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ABSTRACT 
Over centuries, world populations exclusively have used medicinal plants as 
therapeutic agents. Currently, some studies have proven that α-mangostin, a natural 
xanthone isolated from part of Garcinia mangostana L. tree especially from stem bark or 
fruit rinds has many potential activities including antioxidant, anti-bacterial, antivirus, anti-
inflammatory, and anticancer that has resulted in many mangosteen products appearing on 
the market. To standardise and quality control mangosteen and herbal products in general, 
an acceptable reference standard which is isolated from the plant itself is required. 
Separation and purification techniques using liquid flow processing known as counter-
current chromatography (CCC) are widely applied for this purpose. However, generally 
only a single injection of the sample into a CCC apparatus is used due to sample 
complexity. Multiple injections to increase the overall yield and scale of the purification are 
seldom used. But this has the advantage of reducing the cost of the purification process.  
The purpose of this has been to develop an efficient method for production of α-
mangostin reference standard from fruit rind of Garcinia mangostana L. using liquid flow 
processing. The experiment were conducted initially by sample loading studies at analytical 
scale using a Mini HPCCC (17.4 mL coil, 0.8 mm bore) with a hexane/ethyl 
acetate/methanol/water (5:5:10:4 v/v) solvent system. Extract was prepared by overnight 
maceration of mangosteen rinds powder in 80% aqueous ethanol at 30⁰C. The extract in 
lower phase was injected up to 10 times without any replacement or topping up the 
stationary phase. The studies establsiehd 22.8 mg extract in 0.86 mL lower phase as the 
optimum amount of sample with multiple injections; and  produced α-mangostin with 
98.82% purity and 93.68% yield. Scaled up 8 times with 10 injections on Spectrum-CCC 
and 50 times with 7 injections on Midi-CCC gave α-mangostin with 99.24% purity and 
96.35% yield; and 98.24% purity and 94.42% yield respectively. The concentration was 
then optimised nearly 3 times on Spectrum giving α-mangostin with 98.11% purity and 
93.81% yield. These α-mangostin products with purity >98% can be accepted as reference 
standard for quality control of mangosteen based products, allowing the precise calibration 
of analytical instruments with this target compound. The purified α-mangostin was 
identified using commercial reference standard on HPLC and NMR. 
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Chapter 1 INTRODUCTION AND LITERATURE REVIEW 
1.1 INTRODUCTION 
1.1.1 Traditional Herbal Medicines and the need for standard material 
The World Health Organization (WHO) defines traditional medicine as, “…the sum 
total of the knowledge, skills, and practices based on the theories, beliefs, and experiences 
indigenous to different cultures, whether explicable or not, used in the maintenance of 
health as well as in the prevention, diagnosis, improvement or treatment of physical and 
mental illness”. Herbal medicines include herbs, herbal materials, herbal preparations and 
finished herbal products that contain as active ingredients parts of plants, or other plant 
materials, or combinations (WHO, 2000). To ensure consistent quality which the active 
ingredients have been identified in herbal medicines, WHO requires standardisation to 
contain a defined amount of the active ingredients. Therefore, standard material of the 
active ingredients from medicinal plants must be provided to meet the needs. 
For centuries, medicinal plants have been used as traditional medicines to treat 
many diseases. Traditional use refers to the long historical use of these medicines. Their use 
is well established and widely acknowledged to be safe and effective, and may be accepted 
by national authorities (WHO, 2000).  Currently, in spite of the exponential development of 
synthetic pharmaceutical chemistry, including combinatorial chemistry and microbial 
fermentation, 25% of prescribed medicines in developed countries are of plant origin. This 
percentage can reach 50% for the over-the-counter (OTC) market (drugs for self-
medication). In fact, it is also estimated that natural products are used in the development of 
44% of all new drugs, especially for the preparation of semi-synthetic derivatives. 
Nowadays, the pharmaceutical industry fully considers plants as a viable option for the 
discovery of new leads (Hostettmann,  2001).  
Indonesia has its own traditional medicine which is a generations heritage called 
“Jamu”. It is predominantly herbal medicine made from natural materials, such as parts of 
plants i.e. roots, leaves, bark, and fruit. Some times, there is also material from the bodies 
of animals, such as bile of goat or alligator (Anon2). The Policy of the Jamu is governed by 
the Ministry of Health; however the monitoring of the products were undertaken by the the 
National Agency of Drug and Food Control of the Republic of Indonesia (NADFC-RI).  
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To anticipate the increasing number of the natural products in the market of 
Indonesia, NADFC-RI needs to consider tools for controlling the products. Analytical 
methods for controlling the products should be developed especially to ensure the quality, 
safety and efficacy as a domain of the institute. However, to apply the methods either 
qualitatively or quantitatively, an acceptable reference standard needs to be provided. The 
standard can be an active compound (a biologically active molecule which is often the main 
ingredients in pharmaceuticals) or a marker compound (a compound used as an internal 
standard or to label particular batches) depending on the analytical purposes. Usually, a 
marker compound is used to ensure the content of the product, to avoid product 
counterfeiting, while an active compound is needed as a standard when the quality and 
efficacy of the product needs to be ensured. According to the WHO, if the identification of 
an active principle is not possible, then it should be sufficient to identify a characteristic 
substance or mixture of substances (e.g. “Chromatographic fingerprint”) (WHO, 2000) 
1.1.2 Preparation of standards; a role for Counter-current Chromatography (CCC) 
Preparation of a marker or active compound from a medicinal plant is not a simple 
task because there will be a long procedure to extract and isolate, as well as purify and 
identify the compounds which can be very complex molecules. To determine and isolate 
such compounds from the medicinal plant, it is important to understand its physical and 
chemical properties. The target may be a major compound that is easily found and isolated; 
otherwise an advanced purification method should be developed when the compound is 
difficult to separate. Using a classical method like column chromatography is not always 
satisfactory due to the possibility of column blockage with particulates from the crude 
sample, column properties changing with time and the expense of replacing the column 
material. There will be occasions when an alternative and efficient method therefore needs 
to be developed, and liquid flow processing known as counter-current chromatography 
(CCC) seems to be suitable for this purpose. CCC is an excellent alternative to avoid the 
problems associated with solid-phase adsorbents and to preserve the chemical integrity of 
mixtures subjected to fractionation. Furthermore, the advancing technology of CCC is easy 
and predictable to be scaled up (Doshi, 2010; Sutherland, 2009).  
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1.1.3 The preparation of α-mangostin as a standard using CCC 
To develop an efficient method for the production of α-mangostin, the study 
described in this thesis  was undertaken to develop a one step isolation and purification 
process of to obtain α-mangostin as a standard material  from fruit rinds of Garcinia 
mangostana L., using liquid flow processing (CCC). Importantly, the method developed is 
different from existing methods that have previously been performed. This research was 
undertaken initially on an analytical scale CCC instrument (17.4 mL coil; 0.8 mm bore) 
using Mini High Performance Counter Current Chromatography (HPCCC) and an aqueous 
ethanol extract of mangosteen fruit rinds as a sample. The sample was prepared by 
overnight maceration of mangosteen rinds powder in 80% aqueous ethanol at 30⁰C. To 
produce a high throughput of α-mangostin, the method was developed and optimised by 
increasing volume and concentration of sample with multiple injections up to 10 times 
without any replacement or topping up the stationary phase. The developed method was 
then scaled up on semi preparative Spectrum HPCCC instrument (143.5mL coil; 1.6 mm 
bore) and on preparative Midi HPCCC instrument (912.5 mL coil; 4 mm bore). Using this 
method has some advantages such as simpler; reduce cycle time and less solvent use.  
Moreover, using this method provided α-mangostin with high purity, yield and recovery as 
well as throughput.  
1.2 LITERATURE REVIEW 
1.2.1 Mangosteen and mangostin 
Among tropical fruits, Garcinia mangostana L (mangosteen) is the most popular 
and valued in the family Clusiaceae (Morton, 1987). The origin of the mangosteen is not 
exactly known, but it is believed to come from the Sunda Islands and the Moluccas of 
Indonesia. The mangosteen tree can be described as a slow-growing tree, erect with a 
pyramidal crown; and attains 20 to 82 ft (6-25 m) in height. The fruit, capped by the top 
calyx at the stem end and with 4 to 8 triangular, flat remnants of the stigma in a rosette at 
the apex, is round, dark-purple to red-purple and smooth externally; 1 1/3 to 3 in (3.4-7.5 
cm) in diameter. The rind is 1/4 to 3/8 in (6-10 mm) thick, red in cross-section, purplish-
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white on the inside. The flesh is juicy, slightly acid in flavour and delicious (Morton, 1987). 
Mangosteen fruit can be obtained as fresh fruit, packed in cans, or made into syrup/juice.  
                                            
                     
 
 
     Figure 1.1 Mangosteen fruits 
Mangosteen thrives in most of Southeast Asia countries such as Indonesia, 
Thailand, Malaysia and Myanmar which have tropical climates in the whole year. People in 
those countries, especially in Thailand, have traditional used the hull of mangosteen as a 
medicine for skin infection, wounds, and diarrhoea for many years. In Indonesia, it is 
traditionally used for treating haemorrhoid, thrush and wounds as well. The rinds of the 
fruit are used as a natural dye for textiles and the trunk is used as building materials, and for 
firewood/crafts (Obolskiy, 2009). 
Reviews of mangosteen have been carried out especially in the area of 
phytochemical and pharmacological effect, other traditionally applications, including the 
therapy of various diseases such as dysentery, urinary disorders, cystitis and gonorrhoea 
(Obolskiy, 2009). Currently, some new interesting properties are being reported and 
research on the mangosteen area has been growing rapidly, not only in Asian countries 
where mangosteen originates but also in USA and European countries. It has been reported 
that phytochemical and pharmacological studies on xanthone and their derivatives isolated 
from the mangosteen fruit rind are the most widely performed to explore the benefit 
properties and efficacy of mangosteen as the queen of tropical fruit. Nevertheless, the 
research on toxicity is still very limited and preliminary toxicity studies need to be 
improved to ensure safety in the use of Mangosteen products (Ajayi, 2007). 
It has been reported that a 40% ethanol extract of mangosteen hull could inhibit 
both histamine release and prostaglandin E2 synthesis (Nakatani, 2002). This suggests that 
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the crude extract is promising for both anti allergy and anti inflammatory agent. Other 
researchers have claimed that the crude methanol extract from the pericarp of Garcinia 
mangostana had anti-proliferative, apoptotic and antioxidative properties, so it has the 
potential as a natural cancer chemoprevention agent (Moongkarndi, 2004). Furthermore the 
crude ethanol extract showed α-glucosidase inhibitory activity and elicited a reduction of 
postprandial blood glucose levels that is a potential for anti-diabetes (Ryu, 2011). In vitro 
cytotoxicity studies of lyophilized hot water and juice extract of the fruit rind of 
mangosteen against K562, P3HR1, Raji, and U937 leukemic cells have exhibited a potent 
anti-leukemic activity for the hot water extract (Chianga, 2004).   
The latest in scientific research confirms that mangosteen contains a class of 
naturally occurring polyphenolic compounds known as xanthones. Isolation and 
identification of xanthones and their derivatives: α-mangostin, 8-desoxygartanin, gartanin, 
β-mangostin, 3-mangostin, and 9-hydroxycalabaxanthone has been reported (Walker, 
2007). The results of several research projects show that xanthone has properties which 
include antioxidant activities (Suvarnacuta, 2011; Zarena and Sankar, 2009 a, b; Zarena and 
Sankar, 2012), analgesic and anti-inflammatory (Cui, 2010), anti cancer therapeutics 
(Tangpong, 2011), and Alzheimer’s disease (Moongkarndi, 2010). Many scientists have 
reviewed the medicinal properties of Garcinia mangostana L. extract for antioxidant, 
antitumor, anti allergic, anti-inflammatory, antibacterial and antiviral activities (Caverri, 
2008; Dembitsky, 2011; Kapoor, 2009). It has even been mentioned by other reviewers that 
mangosteen xanthones are effective for treating gastrointestinal disturbances and for 
wound-healing including antifungal, anti malarial, and anti-HIV (Kinghorn, 2011). This 
seems to suggest a potential for development as an anti-virus medicine in the future, 
especially for anti HIV-AIDS virus which no effective treatment is currently available.  
The most medicinally important xanthones isolated from mangosteen are  
α-mangostin and γ-mangostin. Mangostin with molecular formula: C24H26O6; Mol. Wt. = 
410.46, is a natural organic compound isolated from the mangosteen plant. It is a yellow 
colour, crystalline solid with a xanthone core structure (The Merck Index, 13th edition 
2001). This mangostin has density of 1.265 g/cm3; melting point of 180-182 ºC, boiling 
point of 640.1 ºC at 760 mmHg and flash point of 220.3 ºC. It is a specific chemical 
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compound in mangosteen so it can be used as a marker for the analysis of mangosteen. The 
chemical structures of α, β, and γ-mangostin are as follows:  
 
                                          
Figure 1.2 Chemical Structures of Mangostins (Pothitirat and Gritsanapan, 2008) 
 
Alpha-mangostin: R1 = CH3, R2 = R3 = H 
Beta-mangostin: R1 = R3 = CH3, R2 = H 
Gamma-mangostin: R1 = R2 = R3 = H 
Mangostin has been shown to have an analgesic and anti-inflammatory effect (Cui, 
2010; Chena, 2008), antioxidant and neuroprotective effect (Chaverri, 2009; Chin, 2008; 
Abundis, 2010), cytoprotective effect (Sampath and Vijayaragavan, 2008), anti-acne 
producing bacteria (Pothitirat, 2009), anti-melanoma agents (Wang, 2011), abscess and skin 
infection (Tewtrakul, 2009), inflammation, pain and neuropsychiatric symptoms effects 
(Sukma, 2011), moderate inhibitory effects on cAMP phosphodiesterase (Chairungsrilerd, 
1996), Alzheimer’s disease (Moongkarndi, 2010), potent inhibitory activity of 
prostaglandin E2 (Nakatani, 2002), renoprotective effect against cisplatin-induced renal 
damage in rats (Pérez, 2010), preventive and therapeutic application for cancer treatment 
(Matsumoto, 2004), reduced [Ca2+] elevation by suppressed Ca2+ influx/ Inhibitory effect 
on rat basophilic leukaemia RBL-2H3 cell de-granulation (Itoh, 2008), in vitro cytotoxicity 
against human colon cancer DLD-1 cells and effective chemo-sensitizer (Nakagawa, 2007), 
and significant anti-mycobacterial activity against Mycobacterium tuberculosis 
(Arunrattiyakorn, 2011). Recent investigations of the anti tuberculosis potential of 
mangosteen revealed that tovophyllin B possesses a significant inhibitory activity against 
Mycobacterium tuberculosis (MIC = 25 lg/mL). Direct synthesis of α-mangostin has been 
established by researchers from Japan (Iikubo, 2009). After assessment they concluded that 
the α-mangostin was a potent inhibitor against the acidic sphingomyelinase cause of death 
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in early childhood. Mangosteen can also enhance the clinical effect of periodontal treatment 
(Rassameemasmaunga, 2008) and shows excellent apoptotic effects on head and neck 
squamous cell carcinoma (Kaomongkolgit, 2011). It can potentially be developed as a new 
medicine for anti-inflammatory and anti cancer.  
On the other hand research on mangosteen, especially on pericarp or shells, has 
grown not only for pharmacological investigation but also for cosmetic application as 
ageing control, anti-acne and natural dye (Pothitirat, 2009; Zhou, 2011). Mangostin shell 
was effective in removing low concentrations of toxic metal such as lead, zinc and cobalt, 
so it might be useful for water purification or other related purposes (Zein, 2010). Since 
mangosteen has been shown to have strong antioxidant activity, research on mangosteen 
has developed in the area of nutraceutical and food additive, so that xanthones from 
mangosteen are claimed as phytonutrients, natural antioxidant, and food preservative 
(Kapoor, 2009; Dembitsky, 2011; Zhou, 2011). In addition, pelargonidin 3-glucoside that is 
contained in mangosteen was also investigated to be a natural colorant in food and use of 
this new natural colorant has increased (Zarena, 2012). Moreover, a group of Indian 
researchers have reported that the leaf extract of mangosteen can be used as a reducing 
agent when doing biologically synthesised nanoparticles that are highly effective against 
different multi-drug resistant human pathogens (Veerasamy, 2011).  
Because of the widely varied potential benefits of Mangosteen and its derivatives 
for drug, traditional medicine, food supplement, cosmetic and food additives, it can be 
estimated that in future there will be more mangosteen products produced and offered by 
pharmaceutical and food supplement industries to meet market needs.  
1.2.2 Isolation of mangostin  
Separation and isolation of α-mangostin and other xanthones from mangosteen have 
been performed by different researchers in several ways in order to obtain the maximum 
amount of Component. However, they generally used maceration at room temperature with 
a wide variety of organic solvents such as methanol, ethanol, butanol, ethyl acetate, 
chloroform, hexane, and ethyl chloride for extraction and isolation; and used column 
chromatography for fractionation as well as purification. A α-mangostin isolation 
processing was developed and patented in the USA by Boehringer Ingelheim Pharma 
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Company in January 2006 using several steps with various aqueous alcohol and aromatic 
solvent of 1.2-ethanediol and toluene in preferable temperature range 60-80⁰C. The crude 
product was purified in a Kühni column and using this method, the quantity of α-mangostin 
extracted was 2.48% of the crude in the toluene extract (Sobotta, et. al., 2006).  
An isolation method by Marquez-Valadez et al. (2009), repeated by Caverri  (2009), 
used silica gel column chromatography eluted with hexane/CH2Cl2 (from 4:6 to 0.1) after 
macerating by CH2Cl2-MeOH (1:1). The amount of α-mangostin was 3.15% (Caverri, 
2009). An extraction method has also been performed by Rahmania, in Research Center for 
Drug and Food of NADFC-RI (personal communication) which gave 1.66% of α-
mangostin. The method employed macerating the crude mangosteen rinds powder in 80% 
ethanol in water at room temperature for 24 h with occasionally stirring. The maceration 
was repeated until colourless solvent was obtained and the macerates were pooled. The 
solvent was removed by rotary evaporator to yield a concentrated extract. The ethanol 
extract was then dissolved in 50% methanol in water and partitioned 3-4 times in a 
separating funnel using n-hexane for 15 min each to remove non polar compounds. The n-
hexane phase was removed from the funnel and ethyl acetate added to the methanol-water 
phase and shaken. The addition of ethyl acetate was repeated 3-4 times until the layer of 
ethyl acetate was colourless. The ethyl acetate phase was collected and dried down using a 
rotary evaporator and then fractionated by column chromatography with silica gel 60 as the 
stationary phase and eluting with a number of n-hexane-ethyl acetate mixtures which had 
different concentration of n-hexane from 10% to 90%. There were 31 fractions divided into 
6 combined fractions which had the same TLC profile from the eluent of n-hexane/ethyl 
acetate (8:2 v/v). Fractions with the same TLC profile were combined and the solvent was 
removed using a rotary evaporator at 40-50⁰C. The extract was crystallized and re-
crystallised using methanol and n-hexane. The crystals were analysed by TLC. From the 
TLC analysis, 2 spots were observed therefore the crystal was purified further using 
Sepacore apparatus (an isocratic flash chromatography technique) with n-hexane/ethyl 
acetate (8:2 v/v) as a mobile phase and analysed again by TLC. The fraction which had 
only one spot on TLC was assumed as pure mangostin. The melting point was measured 
and the sample identified by UV-Vis Spectrophotometer, Fourier Transform Infrared 
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Spectroscopy (FTIR) and Nuclear Magnetic Resonance Spectroscopy (NMR) (Rahmania, 
2009).  
Ee et al. (2006), a group of researchers from Malaysia, have isolated and identified 
α-mangostin, β-mangostin and other xanthones from the finely ground stem bark of 
Garcinia mangostana L. They obtained 0.007% of α-mangostin and 0.005% of β-
mangostin in the n-hexane extract of 1.5 kg mangosteen crude after purifying by column 
chromatography using hexane, hexane/dichloromethane, dichloromethane/ ethyl acetate 
and dichloromethane/methanol as the eluting solvents. The compounds were determined by 
spectroscopic methods such as 1H NMR, 13C NMR, and mass spectrometry (MS) (Ee, 
2006). 
1.2.3 Counter-current Chromatography 
1.2.3.1 Distribution in two- Phase Systems 
Counter-current chromatography (CCC) is a modern technology that is suitable to 
separate individual chemical compounds, or groups of compounds from complex mixtures. 
Therefore it is becoming widely used as a versatile method of purifying a variety of 
materials (Doshi, 2010; Sutherland, 2000). CCC is defined as a liquid chromatography 
(LC) technique that uses two immiscible liquid phases without any solid support (Berthod, 
2009).  
Conventional liquid chromatography employes a single phase to elute the analytes 
released from the adsorptive or liquid phase coated solid support. On the other hand, the 
CCC technique uses a two-phase solvent system made of a pair of mutually immiscible 
solvents, one used as the stationary phase and the other as the mobile phase. The use of 
two-phase solvent systems allows one to choose solvents from an enormous number of 
possible combinations (Ito, 2005). One major advantage of working with a liquid as 
opposed to a solid stationary phase is that the solutes have access to the whole volume of 
the stationary phase (Berthod, 2007).  
A unique advantage of CCC is the ability to change the elution mode by simply 
selecting which of the two liquid phases is the mobile phase, effectively selecting either 
normal or reverse phase mode of elution. Scaling up CCC is also simple because CCC is 
mathematically linear and very predictable. The major challenge of CCC is to obtain a 
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stable support-free liquid stationary phase (Berthod, 2009). Migration through the column 
is controlled by the partition coefficient also known as the distribution ratio (KD) (Conway, 
1995). 
The distribution ratio is a concentration ratio between compounds dissolved in the 
stationary phase divided by compounds dissolved in the mobile phase. A compound with 
KD= 0 will not dissolve in the stationary phase and will come out with the solvent front in a 
time dictated by the volume of mobile phase. A compound with KD= 1 will be equally 
soluble in both phases and therefore elute with the column volume in a time dictated by the 
column volume divided by the flow rate. This effect is measured by the following formula: 
M
S
D C
C
K =
 
CS is the concentration of a sample component dissolved in the stationary phase (SP) and 
CM is the concentration of the same component dissolved in the mobile phase (MP). Good 
KD values are between 0.5 and 2, if KD<0.5 there will be loss of peak resolution. Otherwise, 
if KD>2, long retention time and peak broadening will occur (Doshi, 2010).  
Component elution of sample on CCC can be illustrated in the diagram below: 
  
Figure 1.3 Diagram of Component Elution on CCC (Anon6) 
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The diagram shows the theoretical elution of a compound with a partition 
coefficient/distribution ratio (KD). The liquid–liquid partition ratio of the solute in the 
biphasic liquid system used to perform the CCC separation is the only parameter in the 
retention equation 
SDMR VKVV +=  
Where VM is the mobile phase volume and VS is the stationary phase volume inside the 
CCC apparatus. VM corresponds to the hold-up volume in HPLC (Berthod, 2009). Since 
there is no solid support, the column volume (VC) is calculated according to equation 
below: 
SMC VVV +=  
To calculate the peak elution time (retention time) for any of Components is used 
the following equation: 
( )[ ]11 −+= DfCR KSF
V
t
 
Where VC is the column volume, F is the MP flow rate, Sf is the SP retention and KD is the 
distribution ratio. Running CCC with the same conditions will provide the same retention 
time of the target peak. Once the system is developed, prediction of elution times is easy 
(Conway, 1995). 
On CCC running where two liquid-liquid phase systems are used, the column is 
simply filled with the stationary phase (SP) by pumping at a high flow rate without rotation 
until at least one complete coil volume. The mobile phase is pumped at the chosen flow rate 
with column rotation at the desired speed. The displaced volume of SP is measured using a 
graduated cylinder. When the displacement of SP ceases, the column has reached a state 
called hydrodynamic equilibrium and the column is ready for injection. Since the 
displacement volume and the column volume are known, the amount of stationary phase 
left in the column can be calculated and predicted exactly. The compounds will elute based 
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on their distribution ratio (partition coefficient). The stationary phase retention factor (Sf) is 
calculated using the following formula: 
100% ×−=
C
DISPC
f V
VVS
 
Where VC is the known column/coil volume and VDISP is the displaced volume of SP in a 
graduated cylinder. Larger retained stationary phase (Sf ) values mean that the column 
capacity available for the separation is greater and resolution is enhanced. There are mainly 
two different ways to obtain a liquid stationary phase, using centrifugal forces, the 
hydrostatic way and the hydrodynamic way (Berthod, 2009). 
In separations by chromatography, resolution is directly influenced by the ratio of 
SP volume (VSP) and MP volume (VMP) i.e. the higher the ratio, the better the resolution 
will be.  
MP
SP
S V
VR ∝
 
The efficiency of the separation can be expressed in terms of peak resolution (Rs) using a 
conventional equation, 
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Where V, t and W indicate the retention volume, retention time and the peak width of the 
specified peaks, respectively (Ito and Yu, 2009). VRA is retention volume of the earlier and 
VRB is retention volume of the later eluted peaks. WA and WB are their respective base 
widths. The resolution of adjacent peaks is also given by: 
BA
S WW
ZR
+
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Where ∆Z is the separation between peaks A and B; and WA and WB are the widths at the 
base of peaks A and B, respectively. 
Acceptable resolution is on the order of RS = 1.0, and baseline resolution between 
two peaks (as shown in the figure below) requires an RS > 1.5  
 
Figure 1.4 Chromatographic resolutions 
Berthod et al demonstrated very well in the chromatograms of the figure below that 
chromatographic resolution declines dramatically as SF decreases: 
         
 
Figure 1.5 Correlation between retention volume of stationary phase (Sf) and 
chromatographic resolution on CCC (Berthod,  2009) 
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Comparison of chromatograms on Figure 1.5 obtained with the same hydrodynamic 
CCC column, the same biphasic liquid system, and the same sample containing 10 
compounds. The volume of stationary phase retained decreased from 108 mL (SF = 90 %) 
to 36 mL (SF = 30 %). Column volume VC = 120 mL (vertical dotted line), average 
efficiency 500 plates (Berthod, 2009). 
1.2.3.2 Hydrostatic (CPC) 
Centrifugal Partition Chromatographs (CPC) was first introduced in 1982. Its early 
use focused on determining octanol–water partition coefficients, the separation of natural 
products and the extraction of heavy metals. In 1990, Foucault and Nakanishi published a 
comparison of several aqueous two-phase systems for the fractionation of biopolymers 
using CPC (Sutherland, 2008). 
There are two column types that can be used to retain a liquid stationary phase, the 
hydrostatic and the hydrodynamic designs. Classical hydrostatic is referred to droplet CCC 
columns which have a single rotational axis and use only gravity to maintain the liquid 
stationary phase, it takes very long elution times (days). Because of the efficiency reason, 
the droplet CCC column is no longer in use today. Modern hydrostatic is referred to CPC 
(Berthod, 2009). The performance of this CPC equipment far exceeds the original gravity 
stabilised Droplet Counter-current Chromatography (DCCC) due to using centrifugal force 
(circa 200g) but the construction mimics DCCC and this design concept does have flaws. 
CPC machines rotate around only one axis.  
CPC is composed of a number of partition channels which are linked in cascade by 
ducts. The single-axis centrifuge generates centrifugal force to retain stationary phase while 
the mobile phases are passing. Mixing and settling take place in individual partition cells 
that compose a group of partition disks (Yoon, 2010). CPC is actually a continuous form of 
counter-current distribution where a series of chambers are fitted circumferentially on a 
disc which is rotated to create a centrifugal force field. Each chamber has a connection 
from the top of one to the bottom of the next. The chambers are initially filled with the 
stationary phase and then the mobile phase is pumped through displacing some of the 
stationary phase and creating a series of chambers with a retained volume of stationary 
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phase and cascade mixing much like a waterfall between the mobile phase and the retained 
stationary phase in each chamber (Sutherland, 2008).  
As mentioned above, CPC is basically hydrostatic like Droplet CCC however; there 
are improvments in mixing and more theoretical plates with rotor spinning and one axis of 
gyration, using centrifugal field to hold a better stationary phase retained than in 
gravitational field, has constant g-field and also provides much faster separations than in 
DCCC (Murayama, 1982). 
 The hydrostatic CCC column can be described as a schematic of CPC below, 
 
 Figure 1.6 Schematic of CPC as a basic of Centrifugal Partition Chromatography 
(Doshi, 2009) 
The schematic reflects the liquid motion in hydrostatic CCC columns in centrifugal 
partition chromatographs. CPC use centrifugal force to speed separation and achieves 
higher flow rates than DCCC (which relies on gravity). CPC can be operated in either 
descending or ascending mode, where the direction is relative to the force generated by the 
rotor rather than gravity. According to the fast and permanent evolution of the cells design, 
the efficiency and flow rate with low back pressure are improved (Doshi, 2009). There is a 
single axis of rotation producing constant centrifugal field and no phase exchanges in the 
connecting ducts. This design reduces the contact time for solute exchange with the 
stationary phase. It also builds a hydrostatic pressure that explains the significant pressure 
drop needed to operate hydrostatic centrifuges. All hydrostatic centrifuges contain two 
rotary seals; one at the top and the other one at the bottom. They are quiet to operate. CPC 
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instruments are generally operated at higher flow rates and higher back pressures (Berthod, 
2009). 
Helix CCC or toroidal coil CCC system is usually run under a centrifugal force. The 
dimensions of the coil are condensed to a design which is convenient for analytical 
separations. The coil is fitted around the periphery of the centrifugal bowl so that the 
radially acting centrifugal force field retains the stationary phase in one side of the coil, as 
in the basic hydrostatic system described above. 
Ito and Yu have introduced a new configuration of the toroidal coil using an 
equilateral triangular core, which improves both retention of the stationary phase and peak 
resolution. The performance of this triangular helical tube has been demonstrated on the 
CCC separation of dipeptide samples with a two-phase solvent system composed of 1-
butanol-acetic acid-water at a volume ratio of 4:1:5, using a rotary-seal-free continuous 
flow centrifuge system (Ito, 2009). 
1.2.3.3 Hydrodynamic 
A hydrodynamic design column has a variable and cyclic centrifugal field produced 
by the planetary rotation of the bobbin around its own axis and the central rotor axis. There 
is contact between the two liquid phases throughout the tubing. In the schematic below, the 
mobile phase is pictured in black and the stationary phase is white (Berthod, 2009). 
 
 Figure 1.7 Schematic view of hydrodynamic design on the liquid motion in CCC 
(Berthod, 2009) 
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In a hydrodynamic column, there is a variable and cyclic centrifugal field produced 
by the planetary rotation of the bobbin around its own axis and the central rotor axis. 
(Berthod, 2009). 
The hydrodynamic centrifuges used in the CCC columns have two rotational axes, a 
main axis and a planetary one which generates a variable centrifugal force field. There can 
be any number of planetary axes but the most common are single, double, and triple axes. 
Each planetary axis has a bobbin or spool mounted on it that contains the coils of 
continuously wound metal or plastics tubing. In hydrodynamic columns, it is important to 
know the ratio of the spool radius, r, over the rotor radius, R. This ratio was traditionally 
termed β. Since β is defined in LC as the phase ratio VS/VM so the CCC beta ratio should 
be noted β = r/R. 
 
Figure 1.8 Schematic illustration of the type-J synchronous planetary motion of a 
multilayer coil separation column (Ito, 2005) 
These machines have a continuous length of tubing, the column helically wound on 
a bobbin that rotates on its own axis and which itself rotates around a central axis to 
achieve a planetary motion. This motion sets up an oscillating hydrodynamic force field, 
which causes a mixing and settling step to occur with each revolution of the bobbin. This 
hydrodynamic force field also leads phases of differing density to travel to opposite ends of 
the coil; this phenomenon alone retains the SP. The benefit of this design is it operates at 
low pressure, which allows higher mobile phase flow rates and hence shorter separation 
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times. This apparatus has been developed to High Performance Counter Current 
Chromatography (HPCCC) which produces relatively high stationary phase retention 
across the complete range of biphasic systems used so there is reduced cycle time and 
hence increased throughput (Ito, 2005).  
A simply installation of HPCCC can be figured as a schematic diagram as follows: 
 
Figure 1.9 Schematic layout of a typical CCC set-up (Garrard, 2005) 
The schematic diagram represents a simple installation of HPCCC unit. The HPCCC is just 
a different type of column, replacing the solid stationary phase (SP) column of HPLC or 
Flash. The primary alteration to the system is the fitting of a restrictor downstream of the 
pumps, if the pumps currently operate at high pressures, HPCCC works at significantly 
lower pressures than HPLC. Performing scale-up of purification between differing capacity 
HPCCC instruments is quick and simple. HPCCC instruments create the same operating 
conditions so simply using the volumetric ratio between the two column volumes can 
determine the new sample volume and mobile phase flow rate. A further significant 
advantage concerns sample solubility. Often a limiting factor with HPLC purifications, 
with HPCCC instruments particulates sample can be injected onto the column in either 
mobile, stationary or a mixture of both phases, without affecting the performance of the 
chromatography. 
Counter-current chromatography benefits from a number of advantages when 
compared to the more traditional liquid-solid separation methods i.e. (i) no irreversible 
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adsorption; (ii) total recovery of injected sample; (iii) low risk of sample denaturation, (iv) 
simpler with fewer steps of purification process (Marston and Hostettmann, 2006).  
In addition, there are several other strengths which researchers consider for CCC, 
such as CCC can cope with a wide range of radically different polarity compounds; allows 
particulates and extract solid samples; achieves > 99 % purity of Components from 
complex samples; takes extremely complex matrices, such as natural product extracts and 
heart cut target polarities, bio-actives etc without risk of on-column degradation or 
adsorption; uses exactly the same type of liquid pumps, injectors, switching valves fraction 
collectors etc as HPLC or flash chromatography; scale up is linear and predictable etc. 
(Doshi, 2010). 
1.2.3.4 Use for natural products  
Nowadays, research on natural products is rapidly growing, especially on isolation 
and purification of the active compounds from medicinal plants which will be developed as 
new natural medicines. Regarding these purposes, CCC has become a choice method and 
has made possible the separation of a number of biologically interesting natural products 
that are difficult or impossible to separate by other techniques. Crude extracts of plants or 
other organisms are often too complex for the direct analysis by HPLC. Certain materials 
may irreversibly bind to the packing material or may plug the column inlet filters, and 
hence reduce the column life. Those restrictions do not apply to analytical CCC, which 
represents an interesting method for enrichment and separation of various analytes 
(Berthod, 2009). 
Applications of CCC in analytical chemistry and comparison with other separation 
and enrichment methods have shown that the techniques can be successfully used in the 
purification of plants and other natural products including fermentation. It is almost 
universally applicable on mg scale to multi-gram scale as a preparative purification 
technique for both polar and non polar organic materials as well as inorganic mixtures such 
as rare earths. It has been applied to many classes of compounds, including agricultural 
chemicals, alkaloids, amino acids, peptides, proteins, antibiotics, drug metabolites, dyes, 
food products, flavonoids, glycosides, herbicides, pesticides, pharmaceuticals, optical 
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isomers, saponins, tannins, metals and other inorganic materials. (Berthod, 2009; Conway, 
1995). 
Different types of hydrodynamic (High Speed CCC, cross-axis coil) and hydrostatic 
(toroidal coil) centrifuges can be used for separation and concentration of various 
compounds from plant and different natural products. The quantity of separated compounds 
may range from trace to gram amounts (Berthod, 2009).  
Currently the reasons for increasing application of CCC in the separation of natural 
products include: 
1. Bioactive natural products are frequently found in very small amounts and may 
be lost due to irreversible adsorption in conventional column chromatography.  
2. CCC can enable savings in solvent consumption costs and once optimal 
separation conditions are selected for Components by a reduction in the total 
number of separation steps required (Yoon, 2010).  
The new legislation on traditional herbal medicinal products in China requires them 
to be designated as medicines rather than functional foods. A recent review of the role of 
counter-current chromatography in the modernisation of Chinese herbal medicines clearly 
shows that the use of the CCC technology is growing in China, particularly for isolation 
and purification of natural products including group of flavonoids, alkaloids, polyphenol, 
terpenoid, coumarins etc. (Figure 1.10) (Sutherland, 2009).  
 
Figure 1.10 Pie chart showing the classification of the 363 different compounds 
isolated in the modernisation of Chinese herbal medicines (Sutherland, 2009). 
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In purification of Chinese Herbal Medicines, alkane/alcohol systems are now by far 
the most popular representing nearly 40% of the phase systems used. The usage has 
changed over time. Prior to the year 2000, chlorinated systems were used twice as 
frequently as alkane systems. The decrease in use recently reflects the need to avoid such 
solvents on health and safety grounds. By 2007 alkane systems were used in 70% of the 
papers. More recently, papers have been appearing which use acetonitrile systems and 
acetic acid systems (Sutherland, 2009). Probably the two most commonly used solvent 
systems in the area of natural products for aqueous-organic phase system have been ternary 
chloroform/methanol/water and the quaternary hexane/ethyl acetate/methanol/water 
systems (Conway, 1995).  
1.2.3.5. Use for Proteins and Large Molecules 
CCC has been employed for performing purification of biological samples 
including protein and larger structures, based on partitioning technique using aqueous–
aqueous polymer phase systems. The most common solvents used in this technique are 
polyethylene glycol (PEG)–dextran and PEG–potassium phosphate systems. This 
partitioning of biological macromolecules was first established by Albertsson in the 1950s 
(Shibusawa, 2006). Currently in modern biotechnology, the technique is growing interest 
not only for downstream processing of enzymes but also in efficient methods for the large 
scale recovery and purification of fermentation products, such as intracellular enzymes and 
biologically active proteins which require low to medium purity but the absence of 
interfering activities for industrial catalysts; and the other is required high purity for 
analytical and medical applications (Hustedt, 1985).  
When aqueous two-phase systems (ATPSs) and liquid–liquid partition-based 
counter-current chromatography (CCC) are employed for the separation of large bioactive 
molecules including proteins, DNAs and RNAs, it can avoid risks of sample loss, 
denaturation, and greatly reduce processing time. Biologically active large molecules, such 
as commercially important or potentially important therapeutic proteins, DNAs and RNAs, 
need to be prepared under benign physiochemical milieu to preserve their biological 
activities. There are at least two important factors affecting the maintenance of their 
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bioactivities: the media used for separating and purifying the required large molecules and 
the processing time for exposing these molecules in such media (Guan, 2010). 
Some researchers have developed a new method for the separation of proteins using 
liquid-liquid partition using CCC. It has been reported that the cross-axis coil planet 
centrifuge (X-axis CPC) is useful for partitioning macromolecules with aqueous–aqueous 
polymer phase systems. Performance of the apparatus was evaluated on protein separation 
using an aqueous–aqueous polymer phase system composed of PEG 1000 and dibasic 
potassium phosphate with four multilayer coiled columns. This apparatus would be useful 
for the separation of various bioactive compounds with polymer phase systems (Shinomiya, 
2006) 
Study on the separation of a protein mixture containing of myoglobin, cytochrome 
c, and lysozyme has been done by HSCCC using a two-phase aqueous/reverse micelle-
consisting organic solvent system. Both pH and potassium chloride (KCl) concentration 
gradients were applied in the separations. In addition to efficiency of separation, 
enrichment of protein was also examined at the same time. The study confirmed the 
feasibility of performing protein separation and enrichment in one chromatographic run in 
HSCCC. (Shen and Yu, 2007).  
A review on the recent progress of protein and larger molecules separation in the 
industrial scale-up using liquid-liquid chromatography technique was done by Sutherland. 
This review considers recent developments in centrifugal liquid-liquid partition 
chromatography using aqueous two-phase solvent systems, a gentle host medium for 
biologicals, and the prospect for scale-up and eventual manufacture of high-value 
pharmaceutical products. With the results demonstrated in various machines from different 
manufacturer, the author has highlighted particularly the efficiency of each instrument 
when used in separation i.e. lysozyme and myoglobin. This case illustrates the important 
role of CCC in the use of drug and health supplement development (Sutherland, 2007). 
1.2.4 Counter-current Chromatography and Mangostin  
The major xanthones (α- and γ-mangostins) in mangosteen fruit pericarp (MFP) 
have recently been reported to be isolated at high purity in one step using high-performance 
centrifugal partition chromatography with a solvent system containing petroleum ether/ 
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ethyl acetate/methanol/water (10:5:5:1).From a load of 200 mg crude extract of MFP 55.4 
mg α-mangostin with 93.6% purity and 12.4 mg γ-mangostin with 98.4% purity were 
obtained, with yield of 86.3% and 76.3%, respectively. The xanthones were characterized 
by comparing the retention time and UV spectrum with commercially available standards 
(Shan, 2010).  
Screening and fractionation method for major xanthones in pericarp of Garcinia 
mangostana has been developed using CPC directly interfaced with mass spectrometry. 
Extraction was done by pressurised liquid extraction with ethanol and separated at the semi-
preparative scale by centrifugal partition chromatography (CPC) with a biphasic solvent 
system composed of heptane/ethyl acetate/methanol/water (2:1:2:1, v/v/v/v). Separation 
and identification of the compounds were applied by CPC-electro-spray ionisation MS 
coupling. An additional stream of ethanol/1 mol L−1 ammonium acetate (95:5, v/v) and a 
variable flow splitter were also included, and all the compounds in the solvents used in 
mobile phase for the CPC separation were analysed. The dual mode or elution–extrusion, 
which is less solvent-consuming and faster than the elution mode, was used without loss of 
ionisation and detection (Destandau, 2009; Yoon, 2010).  
A method for extraction of α-mangostin and γ-mangostin from Garcinia 
mangostana was developed as a microwave-assisted extraction (MAE) by Fang, et al. The 
experiment conditions were optimised using orthogonal test and 5 g sample was extracted 
with the optimised conditions. Isolation and purification was performed by high-speed 
counter-current chromatography (HSCCC) with a two-phase solvent system consisting of 
petroleum ether/ethyl acetate/methanol/water (0.8:0.8:1:0.6, v/v) and resulting 75 mg of α-
mangostin at 98.5% purity, and 16 mg of γ-mangostin at 98.1% purity from 360 mg crude 
extract of G. mangostana in less than 7 h. The purity of the two xanthones was identified by 
HPLC. Their structures were further characterised by ESI-MS, 1H NMR and 13C NMR 
(Fang, 2011). 
Isolation and purification of major xanthones in another medicinal plant (Swertia 
mussotii) have also been performed on HSCCC using solvent system containing n-
hexane/ethyl acetate/methanol/water (5:5:10:4, v/v/v/v). The experiment conditions were 
reverse phase running at flow rate of 1.5 mL/min, a rotation speed of 800 rpm and a 
temperature of 25⁰C. Using the described method, a 150 mg crude sample yielded 8mg of 
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methylswertianin, 21mg of swerchirin and 11mg of decussatin with purities of over 98%. 
The compounds isolated were determined by 1H-NMR and 13 C-NMR analyses (Jia, 
2011).  
 
1.2.5 High Performance Liquid Chromatography 
1.2.5.1 Principle and Theory 
 Many scientists are very familiar with High Performance Liquid Chromatography 
(HPLC). This instrument is applicable for a wide range purposes; not only for chemical, 
pharmaceutical, cosmetics and food industry but also in agriculture, environment, mining 
and many other purposes including biomedical as well as veterinary, where the sample is 
blood and other biological fluids (Levin, 2001). In drug clinical trials, HPLC plays an 
important role for the determination of bioavailability and metabolite level of a drug in the 
human body. It is also important in forensic science to analyse an unknown sample 
obtained from a crime scene or victim. In phytochemical studies, chromatography is 
commonly used, particularly for fingerprinting analysis, extraction, isolation, purification 
and analysis of Components in medicinal plants or natural resources.  
 Chromatography was invented by a Russian botanist, Mikhail Tswett around 1906 
when he separated pigments of a plant by organic solvent as a mobile phase and chalk as a 
stationary phase. In 1941, Martin and Synge developed liquid-liquid partition 
chromatography which led them to winning a Chemistry Nobel Prize in 1952 (Harris, 
2005). The chromatography word comes from “chromos” meaning colour and “graphos” 
meaning writing, therefore literally “colour writing”. Now, it is considerably more 
sophisticated, however there are still some basic principles that must be applied for 
successful operation of a chromatography system. 
 Chromatography is a physical method of separation in which the components to be 
separated are distributed between two phases, one of which is stationary (stationary phase) 
while the other (the mobile phase) moves in a definite direction (Eti're, 1993). There are 
many different types of chromatography depending on the mobile and the stationary 
phases. Chromatography which uses liquid as the mobile phase is called liquid 
chromatography (LC) and gas chromatography (GC) is chromatography where gas is used 
as the mobile phase. According to the stationary phase, liquid chromatography is divided 
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into several types such as HPLC, Flash Chromatography (FC) and Supercritical Fluid 
Chromatography (SFC) when the stationary phase is a solid. On the other hand, Counter 
Current Chromatography (CCC) and Centrifugal Partition Chromatography (SPC) are the 
types of liquid-liquid chromatography. In addition, there are two types of GC i.e. Packed 
Column Gas Chromatography with a solid as a stationary phase and Gas Chromatography 
with liquid as a stationary phase.  
In general, liquid chromatography can be defined as an analytical chromatographic 
technique that is useful for separating ions or molecules dissolved in a solvent. The sample 
is poured onto the top of the column followed by the solvent system. LC separation 
mechanism is due to differences in adsorption, ion exchange, partition, or size. If the 
sample solution is in contact with the solid or liquid stationary phase, the different solutes 
will interact with the other phase with different degrees and allow the mixture components 
to be separated from each other and determine the transit time of the solute through the 
column. Sometimes the column contains active solids (adsorption), ionic groups on a resin 
(ion-exchange), liquids on an inert solid support (partitioning), or porous inert particles 
(size-exclusion). The compounds are separated by accommodating the solution from the 
column effluent with the time (Tissue, 2000). The schematic can be seen in Figure 1.11.            
                                                     
            Figure 1.11 Schematic of a simple liquid chromatographic separation (Tissue, 2000) 
Chromatography can be preparative or analytical. The aim of preparative 
chromatography is to isolate as much as possible of the desired component from a complex 
sample mixture. It can also serve to separate the components of a mixture for further use 
and to purify large scale of products. Furthermore, it is also used in ultra trace separations 
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where disposable columns are used once. Conventional LC is most commonly used for 
these purposes. Otherwise, analytical chromatography is used to obtain quantitative and 
qualitative information about the compound of interest (analytes) in a sample. Analytical 
chromatography is done normally with smaller amounts of material and is used for 
measuring the relative portions of analytes in a mixture. Analytical separations of solutions 
for detection or quantification normally use more sophisticated HPLC instruments (Levin, 
2001; Lindholm, 2004). 
As an analytical technique, HPLC is usually projected for the separation and 
determination of organic and inorganic solutes in any samples. However, HPLC can also be 
preparative because it is basically a highly improved form of column chromatography. The 
solvent is forced through under high pressures of up to 400 atmospheres on HPLC while 
column chromatography uses gravity. That makes HPLC much faster and allows a very 
small particle size for the column packing material, which provides a much greater surface 
area for interactions between the stationary phase and the molecules flowing past it. So a 
better separation of the mixture will be obtained. In addition, another major improvement 
concern the detection methods which can be used. These HPLC methods are highly 
automated and extremely sensitive (Clark, 2007). In principle, all LC and HPLC work in 
the same way, however HPLC is more efficient, sensitive and easier to operate. HPLC is 
now becoming one of the most dominant instruments in analytical chemistry, not just 
because of ability to separate, identify and quantify the compounds, but parts per trillion 
[ppt] sample may easily be identified by HPLC (Anon, 2011). 
The instrumentation components in HPLC system are the pump, injector, detector 
and data station, whereas the chemical components are the mobile phases and the stationary 
phases (Levin, 2001). Sometimes, HPLC is connected to an auto sampler that makes it 
easier to inject and allows the analyst to analyse samples in large numbers (usually up to 
100 samples) for unattended automatic operation. A schematic of the HPLC system can be 
seen in figure 1.12.  
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Figure 1.12 Schematic of an HPLC System (Levin, 2001). 
 Running an HPLC can be conducted by injection of liquid sample in a small volume 
into a column (stationary phase) where the individual components of the sample are moved 
down with mobile solvent forced at high pressure using a pump. These components are 
separated by the column packing contains various chemical and/or physical interactions 
between their molecules and the packing particles. These separated components are 
detected by a detector that measures their amount. This detector produces a chromatogram. 
An auto sampler is an important alternative device for the ease of the analyst when a lot of 
samples need to be analysed at the same time, such as in drug clinical trials analysis or 
further analysis for preparative chromatography fractions. 
 In many respects HPLC and Gas Chromatography (GC) are complementary 
techniques. HPLC is the recommended technique for wide range of sample types whose 
analysis by GC can be quite difficult. High boiling or non volatile samples, proteins, 
polymers, ionic compounds, and thermally unstable compounds are all candidates for 
analysis by HPLC. Volatile samples, especially in complex mixtures, on the other hand, are 
more appropriately analyzed by GC. HPLC typically offers more flexibility than does GC. 
These results in part come from the participation of the mobile phase (the solvent system) 
in the separation of chemistry of HPLC (Harris, 2005).   
Based on interactions between the sample, stationary phase and mobile phase, most 
of the separations by HPLC can be placed in one of five categories called modes. (1) 
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Reverse-phase LC is based on distribution of the sample between a polar mobile phase 
(usually water-containing) and a non polar stationary phase. (2) Normal-phase LC is 
generally intended that the mobile phase is non polar compared to the stationary phase. In 
practice, normal-phase LC is often used synonymously with “adsorption’ chromatography. 
It is driven by interaction between the sample and the solvent with polar active sites on the 
surface of the packing material. (3) Ion-exchange LC, as the name implies, depends on 
exchange of sample or buffer ions between the mobile phase buffer and charged groups on 
the stationary phase. (4) Ion-pair chromatography uses a reversed-phase column and a 
“soapy” ion-pair reagent to create an ion exchange system. (5) Size-exclusion 
chromatography separates on the basis of the extent to which the sample molecule can 
penetrate the pores of the packing material. As the name implies, the separation is based on 
molecular size (Dolan, 2007). There are seven basic considerations in choosing HPLC 
operating parameters to work with i.e. solubility, molecular weight, functional groups, 
sample matrix, levels in matrix, detection ability, and how the species differ (Levin, 2001).  
Detection in HPLC can take advantage of a wide range of sample and solvent 
characteristics. Compared to GC that has Flame Ionization Detector (FID), LC lacks the 
sensitive/universal detector. Commonly used HPLC detection techniques include ultra 
violet (UV) or visible light absorbance, refractive index or conductivity monitoring, 
fluorescence measurement, amperometric or coulometric redox, chemical dramatisation, 
and even more elaborate techniques such as chemiluminescence or mass spectroscopy. The 
most common is the UV detector, known as photodiode array (PDA) when it can measure a 
wide range of UV wavelengths at once. UV detection requires the compounds to absorb 
UV light. Conjugation of the molecule does this i.e. an alternating double bond, single 
bond, double bond. Therefore aromatic compounds show the absorption but fats and sugars 
typically do not. For them, another detection method must be employed, such as 
evaporative light scattering detection (ELSD). This is another common detector which is 
destructive, so it is not used on preparative systems, but is universal as long as all 
components have a boiling point higher than that of the solvent used for the mobile phase. 
PDA detection, the most common HPLC detector, generates 3D data which can be viewed 
in 3 ways as 2 dimensional data with 2 axes. 
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1.2.5.2 Column Characteristic  
 The column is considered the “heart of the chromatograph”. In conducting an 
analysis using the HPLC, selection of the column or stationary phase is very important for 
the purpose of analyte separation because an inappropriate column might cause inefficient 
separation. Characteristics of a good column are influenced by several factors such as pore 
size, particle shape and size distribution as well as the length and diameter of the column 
itself. Substrate materials inside the column are also critical in affecting of separation. 
Usually the column contains silica or polymeric substrates of different pore size. Pore size 
can be defined by the ability of the analyte molecules to penetrate inside the particle and 
interact with its inner surface (Levin, 2001). In this case, the column packing and the 
mobile phase are the most important factors in successful HPLC analysis. 
 Several types of column can be selected in the application of HPLC depending on 
the purpose. A column for analytical purposes usually has an internal diameter (i.d.) 1.0-
4.6-mm; lengths 15–250 mm while for preparative purposes the i.d. > 4.6 mm ; lengths 50–
250 mm. Capillary columns are also used for analytical HPLC and usually have i.d. 0.1-1.0 
mm in various lengths. This column offers performance plus flexibility, versatility and ease 
of use. Nano column is a capillary column which has i.d. < 0.1 mm or sometimes stated as 
< 100 µm.  
Materials of construction for the tubing usually are metal which is chemically inert 
to virtually all common solvents and buffers and easy to cut, however has disadvantages 
including limited pressure capability, permeability to air and oxygen and tendency to cold 
flow; stainless steels (the most popular gives high pressure capabilities); glass (mostly for 
bio-molecules) and polyether ether ketone (PEEK) that can be operated at elevated 
pressure, biocompatible and chemically inert to most solvents except tetra hydro furan 
(Dolan, 2007).  
Another thing that is also important is the effect of the separation mode. The 
chemical and physical properties of the analyte should be considered too. Analytes with 
low to intermediate polarity and high solubility in low-polarity solvents will get a better 
separation in normal phase chromatography while water-soluble analytes are usually not 
good candidates for normal-phase chromatography. Reverse phase chromatography using a 
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RP-column is useful for the separation of compounds having high to intermediate polarity 
and ion-exchange chromatography separates analytes by their ionic functionality 
 
1.2.5.3 Isocratic and Gradient 
Solvent composition of the mobile phase in a chromatography creates the chemical 
environment for the interaction between the solutes and the stationary phase. Separation 
can be achieved by controlling and manipulating these interactions, which affect the 
relative retention times of the various sample components.  
Mobile phase parameters which influence retention and separation in reverse-phase 
includes type of modifier, solvent strength, pH, type of buffer, ionic strength and ion-
pairing reagents. Most separations on HPLC are done with reverse-phase, probably over 
90%. In reverse-phase separations of organic molecules, separations are based on their 
degree of hydrophobicity. There is a correlation between the degree of lipophylicity and 
retention in the column. In normal-phase HPLC, the polar solutes elute later than non-polar 
lipophylic ones (Dolan, 2007). 
There are two modes of operation for mobile phase composition: 
1. Isocratic Elution which has constant solvent composition where mobile phase 
polarity stays constant throughout elution process. Isocratic elution creates 
increasing dispersion as a function of efficiency (N), void volume (VO) and 
retention (k), causing lower sensitivity for more retained solutes. Isocratic elution is 
best for simple separations and often used in quality control applications that 
support a manufacturing process. This is equivalent to isothermal separations in GC. 
2. Gradient Elution where mobile phase composition (and thus polarity) varies 
throughout elution process. Gradient elution focuses sample components at the 
column inlet and creates uniform dispersion of all solutes by reducing and 
eliminating the retention factor aspect. This is best for the analysis of complex 
samples and often used in method development for unknown mixtures. This is 
equivalent to temperature programming in GC. Linear gradients are most popular.  
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1.2.5.4 Acidic Additives to Mobile Phase 
The acidity or alkalinity of the mobile phase can have a significant effect on 
separation. Acetic acid and triethylamine are two traditional mobile phase additives that are 
commonly used in reverse phase HPLC (Li, 2010). An acid mobile phase additive impacts 
the retention behaviour of pH-sensitive compounds.  
The use of mobile phase additives might enhance the separation and resolution of 
the bioactive compounds in the HPLC analysis of a medicinal plant. However this must be 
considered with the nature of particle substrates contained in the column itself. The C18 
column for example, which has a hydrocarbon bonded phase, will be damaged if the pH is 
higher than 8.0. That is why using sodium hydroxide solution as a mobile phase additive in 
C18 and C8 columns must be done with care. On the other hand, the silica contained in the 
C18 column will dissolve when the pH is less than 2.0. Therefore, for longer life the column 
which has chemically bonded carbon and silica inside, the pH should be ranged between 
2.0 to 8.0. It is also important to wash column from acid because leaving the column 
overnight with acid from the mobile solvent will make the silica porous and destroy the 
column in a short time (Dolan, 2007). 
1.3 OBJECTIVES 
1.3.1 General Objective 
The increasing number of various herbal medicines and complementary products on 
the market requires reliable quality control and standardisation of the products to protect 
the consumers. This requires acceptable reference standards for qualitative and quantitative 
analysis of the products. This study aimed to develop an efficient method for isolation and 
purification of natural compounds from medicinal plants as reference materials for quality 
control and standardisation of the products using liquid flow processing The production of 
purified α-mangostin from Garcinia mangostana L. rinds in one step is used as an example. 
 
1.3.2 Specific Objectives 
• To provide a reference standard with high purity and yield for quality control and 
standardisation of natural based products 
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• To isolate and purify natural compounds from a medicinal plant using liquid flow 
processing 
• To develop a method for isolation and purification of α-mangostin using liquid flow 
processing 
• To optimise a method in analytical scale for the production of α-mangostin with high 
purity and yield with a simpler process, with reduced processing time and less solvent 
use, by Mini high performance counter-current chromatography (HPCCC) 
• To scale up the production of purified α-mangostin using the optimised method from 
analytical scale to Spectrum HPCCC and Midi HPCCC 
•  To ensure the identity and purity of Components through identification and 
characterisation by High Performance Liquid Chromatography (HPLC) with 
comparation to a commercial reference standard, and Nuclear Magnetic Resonance 
(NMR) Spectroscopy 
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Chapter 2 MATERIALS AND METHODS 
2.1 MATERIALS 
2.1.1 Crude Sample 
 
Figure 2.1 Mangosteen fruit, rinds powder and ethanol extract 
The dry powder of mangosteen (Garcinia mangostana L.) fruit rinds, as a sample of 
this research, was purchased from Bina Agro Mandiri Yogyakarta Indonesia. The 
mangosteen sample was collected from Kulon Progo area in February 2011. The drying 
was performed in an oven at 60 °C for 3 hours to ensure the materials were completely dry, 
then were ground into powder and passed through a sieve with 90 mesh size. The dry 
mangosteen rind powder was stored in an airtight plastic container protected from light 
until used. The mangosteen was authenticated by Sujadmiko, Faculty of Biology Gadjah 
Mada University Yogyakarta Indonesia with certificate number 0300/T.Tb./I/2012.  
2.1.2 Reference Standard  
 
Figure 2.2 Reference standard of α-mangostin 
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Reference standard of α-mangostin with purity ≥98% was a product of China; with 
lot number #051M1495V; P code 10011345133; CAS number 6147-11-1; and was 
purchased from Sigma Aldrich (Gillingham, UK).  
2.1.3 Chemicals and Consumables 
 
Figure 2.3 Chemicals   
Organic solvents such as ethanol, hexane, ethyl acetate, and methanol were 
analytical reagent grade. Methanol and trifluoroacetic acid (TFA) for mobile phase on 
HPLC were HPLC grade. Molecular sieve for drying methanol was general purpose grade 
type 4 A with nominal pore size 4 A. The chemicals were purchased from Fisher Chemicals 
(Loughborough, UK). 
 
Figure 2.4 Consumables 
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Consumables i.e. HPLC vials, pipette tips, glass tubes and plastics tubes for fraction 
collection, were supplied from Fisher Scientific (Loughborough, UK). Other consumables 
were disposable syringes and needles (BD PlastipakTM), filter paper (Whatman no 113), 
centrifuge tubes (Eppendorf) and deionised water and HPLC water was purified from a 
Purite Select Fusion pure water system (Thames, UK). 
2.2 APPARATUS  
2.2.1 HPCCC Instruments 
HPCCC was made by Dynamic Extractions (Slough, UK), and employed for the 
separation and isolation of Components including sample loading studies and development 
of an efficient method for production of α-mangostin. There were 3 scales used in this 
project, with specifications presented on table 2.1. as follows:  
Table 2.1 Specifications of HPCCC centrifuges 
PARAMETERS 
MINI 
HPCCC 
SPECTRUM 
HPCCC 
MIDI 
HPCCC 
Image 
 
 
 
Instrument Scale Analytical Semi Preparative Preparative 
Coil volume 
(mL) 
20 22 and 132 1000 
Flow rate 
(mL/min) 
0.5 - 2 0.5 - 12 10 - 80 
Loading (g/run) Up to 0.2 Up to 2 5 to 40 
Rotational Speed 
(@240g (RPM) 
2100 1600 1400 
Approximate 
elution time for 
KD=1 component 
(min) 
20 20 20 
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2.2.2 High Performance Liquid Chromatography (HPLC) 
 
Figure 2.5 Waters Alliance 2695 Separations Module HPLC 
The HPLC was Waters Alliance 2695 Separations Module (Milford, MA, USA), 
equipped with isocratic and gradient pumps at a maximum flow rate of 10 mL/min. The 
instrument was also fitted with an auto sampler with 120 vials configured in five carousels 
of 24 vials each. Detection system was Waters Photodiode Array Detector 2996 and 
Empower2TM Chromatography Data software was employed as a data processor. 
The Empower software is capable of automating method development, archiving methods 
and customizing data reports. This HPLC was used to analyse α-mangostin from crude 
extract and CCC fractions using a commercial reference standard. 
2.2.3 Nuclear Magnetic Resonance Spectrometer 
 
Figure 2.6 Brüker Avance III HD 600 MHz FT-NMR Spectrometer 
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The NMR was Brüker Avance III 600 MHz FT-NMR Spectrometer with Spin 
Works 3 Data Processor (Germany) housed and operated in the Department of Pharmacy 
and Chemistry, Kingston University. The Spin is a software package for acquiring, 
processing and analyzing NMR data, for streamlined convenience. This instrument was 
applied for the characterisation of α-mangostin isolated from the fruit rinds of Garcinia 
mangostana L. 
2.2.4 Supporting Equipment 
 
Figure 2.7 Supporting equipment e.g. (clockwise from top left) rotary concentrator, 
touch mixer, water bath and fraction collector  
 There were several items of supporting equipment that were used in this study, such 
as analytical balance (Sartorius), rotary evaporator (Büchi Rotavapor R205 with Büchi 
Heating Bath B-490), rotary concentrator (Eppendorf Concentrator 5301), fume cupboard 
(Zurich L 12-3),  centrifuge (Sanyo MSE Micro Centaur), touch mixer (Top Mix FB 
15024; Fisher Scientific), vacuum pump (Laboport), water bath (Grant), micropipette 
(Eppendorf), ultra sonic bath (Sonomatic Jencons), fraction collector for Mini and 
Spectrum HPCCC (Teledyne ISCO Foxy Jr.), fraction collector for Midi CCC (Gilson 
Model 202), Rotary wheel (Stuart Rotator SB3), HPLC Column: Agilent Zorbax Bonus RP 
C18 with dimension (3.5um; 4.6x150mm), buchner funnel, separating funnel and glassware 
(Fisher brand).   
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2.3 METHODOLOGIES 
2.3.1 Optimisation of Analytical Method for α-Mangostin by HPLC 
2.3.1.1 Preparation of HPLC Mobile Phase 
Into 1000 ml methanol HPLC grade and 1000 ml fresh deionised water in separate 
containers was added 500 µL TFA each. The mixtures were well shaken and filtered using 
a Millipore filter with pore diameter of 0.45 µm under vacuum condition if needed. The 
mixtures were prepared freshly before use. 
 
 
Figure 2.8 Methanol and water, to which 0.05% TFA was added for the HPLC 
mobile phase 
2.3.1.2 Optimisation of analytical condition for α-Mangostin using HPLC 
Optimisation of analytical condition was conducted on Waters Alliance 2695 
Separations Module HPLC which was equipped with photo diode array (PDA) UV 
detector. An Agilent Zorbax Bonus RP-C18 (3.5µm; 4.6x150mm) column was selected 
among several columns as a stationary phase; run time 12 min; temperature 40°C; detection 
range at 210-400nm with a binary mobile phase consisting of 0.05% TFA in water (solvent 
D) and in methanol (solvent C) at a flow rate of 0.5 ml/min. The gradient elution program 
was as follows: 0-3.00 min, 95-100% C; 3.00-8.00 min, 100% C; next injection at 14 min 
after column equilibration. Data was collected over 12 min run time.  
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The optimised method was then used to assay the standard solution made from 
commercial α-mangostin reference standard and to create a calibration curve; then to 
analyse the crude extract as well as CCC fractions. The low limit of detection (LLOD) was 
determined based on the results of sample measurements that provided a peak height with 3 
times base line noise i.e. signal to noise ratio S/N=3. 
2.3.1.3 Preparation of Standard Solution I 
Standard solution I for the calibration curve of α-mangostin was prepared in the 
following manner: Approximately 1.2 mg α-mangostin reference standard was weighed 
accurately, 5.0 mL dry methanol added by pipette. The mixture was weighed again in order 
to calculate the true volume of methanol added and mixed evenly, labelled as standard 
solution I; and 1 mL was transferred into an HPLC vial, analysed for the calibration curve I.  
The true volume of methanol in the α-mangostin standard solution was calculated 
by the following formula: 
  ρ
MV =
 
V = volume; M = Mass; and ρ = density.  
Methanol density is 0.7918 g cm−3 (value from Wikipedia), approximately 20⁰C which is 
likely to be the room temperature at the time  
Dry methanol was prepared in a flask by adding some molecular sieves into 
methanol HPLC grade, shaken vigorously and left overnight. 
2.3.1.4 Preparation for Standard Solution II 
Standard solution II was a 25 times dilution of standard solution I. Preparation was 
carried out as follows: Into a volumetric flask, 2.0 mL α-mangostin standard solution I was 
pipetted accurately and dry methanol added up to 50.0 mL at temperature of 20⁰C. The 
solution was mixed evenly, labelled as standard solution II. 1 mL was transferred into an 
HPLC vial, analysed for the calibration curve II.  
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2.3.1.5 Preparation for Calibration Curve  
To prepare calibration curves, the standard solution II was injected with successive 
volumes: 2, 5, 10, 15, 20, 25, 30, 40 µL and the standard solution I was injected with 
successive volumes: 2, 5, 10, 15, 20, 25 µL respectively into HPLC with optimised 
conditions as decribed on 2.3.1.2. The calibration curves were created by plotting the 
amount vs. peak area of each standard solution injected. The data from standard solution I 
was plotted for calibration curve I and the data from standard solution II was plotted for 
calibration curve II. 
2.3.1.6 Preparation for Aqueous Ethanol Extract as Stock Solution 
 
 
Figure 2.9 Preparation of aqueous ethanol extract with overnight maceration (left) 
and extract filtration under vaccum (right) 
 
100 gram crude powder was macerated overnight in 700 ml of 80% ethanol at 30⁰C 
with occasionally stirring. The mixture was then filtered under vacuum using Whatman 
filter paper number 113. The pulp was added to 500 mL 80% ethanol, stirred, left for about 
1 hour and filtered in the same manner. The filtrates were combined and the extract yield 
measured before drying down using rotary evaporator at 35 rpm, 45⁰C. To remove water 
from the syrup extract, about 200 mL methanol was added into the extract and drying 
continued. When completely dry, the extract was then re-dissolved in methanol or lower 
phase (LP) accordingly and used as a stock solution for further experiments. 
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2.3.1.7 Measurement of the Extract Yield  
An empty vial was weighed accurately, 5.0 mL macerate added and weighed again. 
The macerate was dried down using a rotary concentrator and the dry extract was weighed 
again until stable. The yield was calculated as a percentage of dry extract in mangosteen 
rinds powder. The measurement was conducted in triplicate. 
 
Figure 2.10 Dry extract from macerates 
2.3.1.8 Crude Extract analysis on HPLC 
 Analysis of the crude extract was performed on HPLC in the following manner: 10-
20 µL of stock solution in LP was transferred into an HPLC vial and dried down using a 
rotary concentrator. 1000 µL methanol was added and mixed well. 5 µL solution was then 
injected into HPLC and analysed under the same analytical conditions as used for the 
preparation of the calibration curve. The peak area of α-mangostin was calculated using the 
calibration curve especially to determine the recovery of α-mangostin injected on HPCCC. 
Sample from stock solution in methanol could be directly injected into HPLC without 
drying down the solvent.  
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2.3.2 Optimisation of an Efficient Method for Production of α-Mangostin using 
HPCCC 
2.3.2.1 Solvent System Selection and Partition Coefficient (KD) Measurement  
Into a vial containing an accurate weight of approximately 5 mg of mangosteen 
crude material was added 5.0 mL of several HEMWat solvent systems from the literature 
study i.e. HEMWat (1:1:1:1 v/v), (5:5:10:4 v/v), (8:8:10:6 v/v) and (10:10:5:1 v/v). 
 
Figure 2.11 Partition coefficient measurement 
The mixtures were shaken and then left to settle for about 30 min until the phases 
were completely separated. Into HPLC separate vials, 0.5 mL upper phase and 0.5 mL 
lower phase of each mixture was delivered respectively and the solvent dried down in a 
rotary concentrator. 1.0 mL methanol was added into the vial and mixed evenly. Before 
analysing in HPLC, if required the mixture was centrifuged at 13,000 rpm for 5 min to 
avoid column blockage by crude particles. The solvent system which had a suitable KD=1 
was selected as solvent system for this study. The experiment was done in triplicate  
2.3.2.2 Settling Time Measurement 
 
Figure 2.12 Settling time measurement using graduated cylinder 
43 
 
The procedure was as follows: the two phases of the chosen HEMWat solvent 
system were first equilibrated in a separating funnel; 2.0 ml of each phase (lower and upper 
phase), a total volume of 4.0 ml, was delivered into a graduated cylinder, which was then 
capped. The container was gently inverted for several times and then immediately placed it 
in an up-right position to measure the time required for the two phases to form clear layers 
with a distinct interface (Ito, 2005). 
2.3.2.3 Extraction Kinetics Studies Using Rotary Wheel 
 
Figure 2.13 Extraction kinetic studies on a rotary wheel 
Into several tubes containing an accurate weight of approximately 250 mg crude 
mangosteen powder each were added 25 mL UP, LP and UP+LP (50:50) respectively. The 
tubes were placed on a rotary wheel and were rotated for 30 min, 60 min, 90 min, 360 min, 
overnight (16 hours), and 2 days. In every completion time, 100 µL extract was taken from 
the tubes into an HPLC vial and dried down using rotary extractor. After completely 
drying, 1.0 mL methanol was added into vial and mixed evenly. The solution then was 
analyzed by HPLC using the same condition as in the calibration curve analysis with an 
injection volume of 10 µL each. The experiment was performed in triplicate. 
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2.3.2.4 CCC Procedure 
2.3.2.4.1 Solvent System Preparation for CCC 
Classical preparation of the HEMWat solvent system for CCC was conducted shortly 
before use by thoroughly mixing hexane/ethyl acetate/methanol/water in ratio of 5:5:10:4 
(v/v) respectively. The mixture was equilibrated in a separating funnel at room temperature 
for about 30 min and the upper phase (UP) and lower phase (LP) separated. The upper 
phase was used for stationary phase and the lower phase used as mobile phase. 
 
Figure 2.14 Solvent system preparations using a separating funnel 
2.3.2.4.2 Sample Preparation for CCC 
To prepare sample for CCC, the extract was dissolved in mobile phase (LP). The 
stock solution dissolved in methanol was dried down and re-dissolved in LP. The 
preparation was done by drying 5.0 mL of the stock solution in a rotary concentrator to 
remove the solvent. The dry extract was  then re-dissolved in LP to the original volume of 5 
mL and used for sample loading studies with dilution using the following equation, 
2211 VCVC ×=×   
Where C1 is initial concentration or molarity, V1 is initial volume, C2 is final concentration 
or molarity, and V2 is final volume. Sample from stock solution in LP could be directly 
diluted at the same manner without drying. 
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Figure 2.15 Dry extract from stock solution in methanol and the extract after re-
dissolving in LP  
 
2.3.2.4.3 Operating CCC 
2.3.2.4.3.1 Analytical Scale Mini HPCCC Centrifuge 
The Mini-CCC centrifuge used for analytical separations and the sample loading 
studies was previously described in detail by Janaway et al (2003). It has a rotor radius of 
50mm, tubing bore of 0.8mm, mean β of 0.74 and a single bobbin of 5.4mL capacity with a 
counter weight. The Mini can be rotated up to a speed of 2100 rpm (246×g) and has a 
typical flow range for most organic/ aqueous phase systems of 0.5–2 mL/min for a 
separation, but the Mini column can cope with flow rates up to 10 mL/min (w.r.t. pressure) 
for refilling (Sutherland, 2009). The system was equipped with one Hewlett Packard series 
1100 pump with 4 different lines that are suitable for 4 different solvents. Detection system 
was a Knauer K-2501 UV detector (Berlin, Germany) which was set at 240 nm to monitor 
the elution process. The fractions were collected using Teledyne ISCO Foxy Jr. fraction 
collector (Lincoln, USA) and the data was processed using Euchrome 2000 Data Processor. 
The operating procedure for Mini was done with equilibration of the column before 
injection. A 50 mL graduated cylinder was placed at the end of the tubing (tail), then the 
stationary phase was initially pumped into the column at a flow rate of 5 mL/min with no 
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rotation until at least one complete coil volume of stationary phase came out into the 
cylinder. The coil was then rotated at 2100 rpm at temperature 25 ⁰C. The mobile phase 
was pumped from head to tail at a flow rate of 1 mL/min. In order to observe the volume of 
stationary phase eluted from the column, the resulting effluent was collected in a 25 mL 
graduated cylinder. The hydrodynamic equilibrium was considered to be established when 
the stationary phase was no longer dripping into the cylinder (usually when the two phases 
volumes of the eluent were approximately equal) and the machine was ready to be injected. 
The sample solution was injected with the desired concentration up to 107 mg/mL or 
volume up to 1.8 mL into the column, the fraction collector started, and the recorder turned 
on. All fractions were collected at 1 min/tube within elution time. At the end of the run, the 
column was emptied of stationary phase by pumping the mobile phase at a higher flow rate 
without rotation. The stationary phase was collected and analysed on HPLC in the same 
manner as on fractions, to ensure all the mangostin had eluted. For multiple injections, the 
injection time was every 25 min. Concentration of α-mangostin was calculated by viewing 
peak area from the calibration curve after analysis by HPLC.  
2.3.2.4.3.2 Semi Preparative Scale Spectrum HPCCC Centrifuge 
The Spectrum HPCCC instrument was initially described by Guzlek et al (2009). 
The equipment that was employed in this project was manufactured by Dynamic 
Extractions (Slough, UK). The machine comes with two sets of two multilayer columns on 
two bobbins, i.e. four columns on two bobbins. These two sets were designated as 
analytical and semi-preparative columns, respectively. Their tubing bore was 0.8 mm for 
analytical coils and 1.6 mm for semi-preparative coils, respectively with 22 and 136mL 
total column volumes. In this study the semi-preparative columns were employed. The β-
value of these coils varied from 0.52 to 0.86. The rotational speed can be varied up to 1600 
rpm and the instrument, which has an integrated temperature controller, was set to 25 ⁰C 
for all runs. The system was equipped with an Agilent Technologies 1200 series isocratic 
pump (California, USA) and detector using photodiode array detection system (Milford, 
MA, USA). The fractions were collected using Teledyne ISCO Foxy Jr. fraction collector 
(Lincoln, USA). 
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Column equilibrium must also be performed before operating Spectrum HPCCC. A 
200 mL graduated cylinder was placed at the end of the tubing (tail), then the stationary 
phase was initially pumped into the column at a flow rate of 40 mL/min with no rotation 
until at least one complete coil volume of stationary phase came out into the cylinder. The 
mobile phase was pumped from head to tail at a flow rate of 4-8 mL/min while the 
centrifuge was rotated at 1600 rpm, 25 ⁰C. In order to observe the volume of stationary 
phase eluted from the column, the resulting effluent was collected in a 100 mL graduated 
cylinder. The hydrodynamic equilibrium was reached when the stationary phase was no 
longer dripping into the cylinder and the machine was ready to be injected. The sample 
solution was injected with the desired concentration or volume into the column, the fraction 
collector started, and the recorder turned on. All fractions were collected at 1 min/tube 
within elution time. At the end of the run, the column was emptied from stationary phase 
by pushing out the stationary phase in each bobbin separately using compressed air at a low 
rotation (215 rpm). The stationary phase was collected in separate cylinder and analysed on 
HPLC in the same manner as on fractions. For multiple injections, the injection time was 
every 25 min. Concentration of α-mangostin was calculated by viewing peak area from the 
calibration curve after analysis by HPLC. 
2.3.2.4.3.3 Preparative Scale Midi HPCCC Centrifuge 
The Midi-CCC centrifuge was manufactured by Dynamic Extractions (Slough, UK) 
and the setup used for the study was described in detail by Hewitson et al. (2009). It has a 
rotor radius of 110mm, tubing bore of 4mm and two bobbins (columns) with a total 
capacity of 912.5 mL. The Midi can be rotated up to a speed of 1400rpm (241×g), has a 
typical flow range of 10–100 mL/min and a mean β value of 0.75 where β is the ratio of 
planet to rotor radius (Sutherland, 2009). This instrument was fitted with a sample injector, 
a Knauer pump K 1000 (Berlin, Germany) which has maximum flow rate 1000 mL/min 
and a Knauer detection system K 2501 UV detector (Berlin, Germany) as on Mini. Data 
processor was Euchrome 2000. The fraction collector was Gilson Model 202 (France). The 
wave length detection was set at 240 nm as optimum wave length of mangostin. 
The operating procedure for Midi was done with equilibration of the column before 
injection. A 1000 mL graduated cylinder was placed at the end of the tubing (tail), then the 
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stationary phase was initially pumped into the column at a flow rate of 200 mL/min with no 
rotation until at least one complete coil volume of stationary phase came out into the 
cylinder. The coil was then rotated at 1400 rpm, 25 ⁰C. The mobile phase was pumped 
from head to tail at a flow rate of 20-50 mL/min. In order to observe the volume of 
stationary phase eluted from the column, the resulting effluent was collected in a 500 mL 
graduated cylinder. The hydrodynamic equilibrium was considered to be established when 
the stationary phase was no longer dripping into the cylinder and the machine was ready to 
be injected. The 50 mL sample solution was injected with the desired concentration into the 
column, the fraction collector started, and the recorder turned on. All fractions were 
collected at 1 min/tube within elution time. The fractions were analysed on HPLC after 
drying down the solvent. At the end of the run, the column was emptied from stationary 
phase by pushing out the stationary phase in each bobbin separately using compressed air at 
low rotation (215 rpm). The stationary phase was collected and analysed on HPLC in the 
same manner. For multiple injections, the injection time was every 25 min. Concentration 
of α-mangostin was calculated by viewing peak area from the calibration curve after 
analysis by HPLC. 
2.3.2.4.3.4  Procedure of analysis for CCC Fractions on HPLC 
 
Figure 2.16 Fraction preparation for analysis on HPLC, fraction drying in a 
rotary concentrator 
Analysis of the HPCCC fractions was carried out on HPLC in the following 
manner: 100 µL of the fraction was transferred into an HPLC vial and dried down using a 
rotary concentrator. 1000 µL methanol was added and mixed well. 5 µL solution was then 
injected on HPLC under the same analytical conditions for the preparation of the 
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calibration curve. All peak areas that appeared on the HPLC chromatogram were plotted on 
a fractogram (a reconstructed chromatogram). These data were used to calculate the purity 
and yield of α-mangostin. From the fractogram, the resolution (RS) between α-mangstin 
and the nearest component peaks (component 3) was calculated using equation on page 13. 
The stationary phase extracted from the column was analysed on HPLC in the same 
manner. 
2.3.2.5 Nuclear Magnetic Resonance (NMR) Spectroscopy Procedure  
This NMR experiments were conducted in Kingston University London. The 
procedure which was done and reported by E Keaveney from School of Pharmacy and 
Chemistry was as follows:  
1. Preparation of initial NMR standard solution, 1 ml of deuterated chloroform was added 
to the vial that contained the alpha-mangostin standard supplied by Sigma-Aldrich. The 
resulting solution was then filtered into an NMR tube through cotton wool in a 
disposable pipette. A drop of TMS (tetra methyl silane) was added to the NMR tube 
which was then shaken to disperse the TMS. 
2. Preparation of second NMR standard solution: the initial NMR standard preparation 
(1) was transferred from the NMR tube to a sample vial. The solution was taken to 
dryness using a stream of nitrogen. 0.75 ml of acetonitrile was added to the sample vial 
using disposable pipettes. The sample was transferred back to the NMR tube by 
filtration through a cotton wool filter using disposable pipettes. A drop of TMS was 
added to the NMR tube and it was covered and shaken to fully disperse.  
3. Preparation of sample: in a vial containing 8 mg sample (indicated pure α-mangostin) 
from a combined HPCCC fractions (EKSM23F2021) prepared by Brunel University 
London, was added 0.75 ml of acetonitrile using disposable pipette. The sample was 
transferred to a glass NMR tube by filtration through a cotton wool filter using 
disposable pipettes and labelled with the sample codes. A drop of TMS was added to 
the NMR tube, which was then shaken to fully disperse and analysed.  
To analyse on NMR, the sample tube was then placed inside a cylindrically wound 
magnet and exposed to a pulsed magnetic field which cause the nuclei within the sample to 
become first excited then relaxed. The resonance produces a signal characteristic to the type 
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of isotope in the sample which is then recorded. This signal is integrated to produce a series 
of spectral lines.  
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Chapter 3 RESULTS AND DISCUSSION 
3.1 Optimisation of Analytical Method for α-Mangostin by HPLC 
Table 3.1 Optimised conditions of HPLC 
No HPLC 
Parameters 
Optimised Conditions of HPLC 
1. Column Agilent Zorbax Bonus RP C18 with dimension 
(3.5um; 4.6x150mm) 
2. Temperature 40 ⁰C 
3. Flow rate 0.5 mL/min 
4. Mobile phase Methanol with 0.05% TFA (C) 
Water with 0.05% TFA (D) 
5. Elution program Gradient system: 
0-3 min: 95-100% C;  
3-8 min: 100% C;  
6. Run time 12 min 
7. Delay time 2 min 
8. Collecting data 12 min 
9. Wave length 
detection 
PDA Max Plot 210 nm to 400 nm 
10 Low limit of 
detection (LLOD) 
0.000008 µg/µL (8 ppm) 
11 Retention time of 
α-mangostin  
6.00 – 6.50 min 
 
As described previously, the optimisation of an analytical method for α-mangostin 
on HPLC began with a literature study. Based on previous research (Jia, 2007; Jujun, 2009; 
Syamsudin, 2010), a C18 column and methanol/water were selected as stationary phase and 
mobile phase respectively for analysing α-mangostin on HPLC.  
In this research, the column selected was Agilent Zorbax Bonus RP-C18 with 
dimension 3.5µm; 4.6x150mm. The column had small particles size that provided a greater 
surface area for interactions between the stationary phase and the molecules flowing past it. 
So a better separation of the mixture was obtained (Clark, J., 2007). In addition, with an 
appropriate dimension of the column, it also produces a good pressure approximately 700 
psi.  
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Analytical conditions were maintained at a temperature of 40 ⁰C where it was a high 
enough temperature to reduce solvent viscosity and the chance of column over-pressure but 
non destructive to α-mangostin and other Components in the extract. The flow rate and 
elution program were set in order to create a chromatogram with good separation. The run 
time of 12 min was optimised to a minimum time that was able to elute all compounds in 
the extract. The delay time was needed to remove all compounds that might remain at the 
end of elution which interfere with the peaks from the next injection. When preparing the 
solvent system for HPLC, 0.05% trifluoroacetic acid (TFA) was added to methanol HPLC 
grade and to fresh ionised water separately as an ion pair reagent to remove tailing of the 
peaks. 
3.2 Preparation of Standard Solution 
Table 3.2 Calculation of α-mangostin standard solution for calibration curve 
Parameters Results 
α-Mangostin 1.2 mg 
Vial and 1.2 mg α-Mangostin 8.2759 g 
Vial and 1.2 mg α-Mangostin + 5.0 
mL dry Methanol 
12.2217 g 
Dry methanol 3.9458 g 
True volume of dry methanol 4.9833 mL 
Concentration of α-Mangostin 
standard solution I 9833.4
1200 µg/mL = 0.2408 µg/µL 
Concentration of α-Mangostin 
standard solution II (25xdilution) 
9.632 µg/mL = 0.0096 µg/µL 
 
Standard solution I was prepared by adding 5.0 mL dry methanol into a vial 
containing an accurate weight of approximately 1.2 mg α-mangostin commercial reference 
standard. After adding the dry methanol, the vial was weighed again to ensure the true 
volume of dry methanol due to minimise errors that might occur in weighing of the 
reference standard. The dry methanol was prepared in a flask by adding some molecular 
sieve into methanol HPLC grade, shaken vigorously and left overnight. This molecular 
sieve was intended to absorb water that probably present in methanol since methanol is 
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hygroscopic. The true volume of methanol was calculated by V=M/ρ; where V is true 
volume of methanol; M is Mass; and ρ is density of methanol (0.7918 g cm−3). Standard 
solution II was 25 times dilution of standard solution I and prepared using the formula of 
C1 x V1 = C2 x V2 (2.3.2.4.2).  
3.3 Calibration Curves 
3.3.1 Calibration curve I 
Table 3.3 Amount of standard solution I injected on HPLC vs. HPLC peak area 
Volume 
(µL) 
Amount  
(µg) 
Peak Area 
(µVolt*sec) 
2 0.4816 4921765 
5 1.2040 15194643 
10 2.4080 31753001 
20 4.8160 64215307 
25 6.0200 80014555 
 
 
 Figure 3.1 Calibration curve I, peak area vs. amount of α-mangostin  
The calibration curve of α-mangostin was intentionally made from 2 different concentration 
of standard solutions to cope with a variety of concentrations of sample/fraction analysed, 
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which have peak areas up to 80,000,000 µVolt*sec. The sample with peak area ≥ 5,200,000 
µVolt*sec was calculated using calibration curve I while peak area < 5,200,000 µVolt*sec 
was calculated using calibration curve II. Both calibration curves either from standard 
solution I or standard solution II had the regression equations with the same R2=0.999 
which mean both curves are linear and using the HPLC optimised method all x values were 
uniformly distributed either side of x ; similarly, all the y values was uniformly distributed 
about y . These calibration curves were used to calculate the amount/concentration of α-
mangostin in all samples including crude extract and HPCCC fractions during this study. 
3.3.2 Calibration curve II 
 
Table 3.4 Amount of standard solution II injected on HPLC vs. HPLC peak area 
 
Volume 
(µL) 
Amount  
(µg) 
Peak Area 
(µVolt*sec) 
2 0.0192 234364 
5 0.0480 643434 
10 0.0960 1295177 
15 0.1440 1965049 
20 0.1920 2629968 
25 0.2400 3313694 
30 0.2880 4017900 
40 0.3840 5392568 
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 Figure 3.2 Calibration curve II, peak area vs. amount of α-mangostin  
3.4 Preparation for 80% Aqueous Ethanol Extract as Stock Solution 
Table 3.5 Sample preparation 
No Crude Material  
(g) 
Dry Extract  
(g) 
Stock Solution  
(mL) 
Yield  
(%) 
1 100 10.6721 62 (in methanol) 10.61 
2 100 15.5898 55 (in methanol) 15.59 
3 200 20.4970 100 (in LP) 10.25 
 
200 20.3816 100 (in LP) 10.19 
 
In an initial study of this project, extraction of α-mangostin using 80% ethanol 
obtained a higher concentration of α-mangostin compare to methanol and ethyl acetate. So 
the solvent was chosen for extraction of α-mangostin from the fruit rinds powder.  
Preparation of the ethanol extract was done with overnight maceration in 80% 
aqueous ethanol, the extract was then filtered under vacuum conditions and collected before 
measuring the yield and drying in a rotary evaporator. Stock solution was prepared by re-
dissolving the dry extract in methanol or in LP. When using stock solution in methanol as a 
sample for separation on HPCCC, the methanol was removed by drying on rotary 
concentrator and then re-dissolved in LP. Otherwise, the stock solution in LP was directly 
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used as a sample on HPCCC without removing the solvent. It was noted; however that the 
stock solution in LP was not as stable as in methanol so it was prepared fresher. Moreover, 
the LP which contains ethyl acetate and hexane will absorbs UV; therefore it needed be 
eliminated from the extract or fraction before analysing on HPLC. 
 
3.5 Measurement of the Ethanol Extract Yield of Mangostin from Crude Material 
Table 3.6 Crude extracts yield measurement 
No Weight 
of 
empty 
vial (g) 
Weight 
of vial 
with 
extract 
(g) 
Weight 
of 
extract 
(g) 
Average 
weight of 
extract 
in 5ml 
(g) 
Total 
volume 
of 
solution 
(mL) 
Total 
weight 
of dry 
extract 
(g) 
Weight 
of crude 
material 
used 
(g) 
Yield 
of 
man-
gostin  
(%) 
1 
7.3126 7.3710 0.0584 
0.0560 947 10.6060 100 10.61 7.3158 7.3630 0.0472 
7.1790 7.2415 0.0625 
2 
7.2713 7.3271 0.0558 
0.0670 1164 15.5976 100 15.59 7.1546 7.2262 0.0716 
7.2948 7.3683 0.0735 
3 
7.3136 7.3670 0.0534 
0.0533 1970 20.9870 200 10.25 7.3211 7.3627 0.0416 
7.1777 7.2425 0.0648 
4 
7.2096 7.2624 0.0528 
0.0530 1924 20.3816 200 10.19 7.1232 7.1763 0.0531 
7.3378 7.3908 0.0530 
 
 Measurement of the yield of ethanol extract was conducted before drying the whole 
filtrates collected using a rotary evaporator. When weighing the dry extract for calculating 
the yield, it was done several times until the weight of the extract was stable to ensure the 
extract was completely dry; so the yield could be calculated accurately. The measurement 
of the yield was actually intended particularly to predict the amount of the extract that 
would be injected to HPCCC for the sample loading study. The range of mass/extract that 
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is possible to be injected depends on the scale of the machine. Table 3.6 shows that 4 
different preparation of ethanol extracts gave the yields 10.19% to 15.59%.   
 
3.6 Crude Extract and Fraction analysis on HPLC 
 
Figure 3.3 Chromatogram of mangosteen crude extract, analysed by HPLC with 
analytical conditions as in table 3.1, injection amount 5µL and concentration loaded 
approximately 0.5µg/µL  
 
 
Figure 3.4 Chromatogram of purified α-mangostin in a sample fraction, analysed by 
HPLC with analytical conditions as on table 3.1, injection amount 5µL and concentration 
loaded approximately 0.1µg/µL.  
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The Chromatograms above show the peak of α-mangostin from analysis on HPLC. 
The α-mangostin peak was the major peak in the chromatogram of the crude extract (Figure 
3.3.) indicating that α-mangostin is a major compound in the fruit rind of Garcinia 
mangostana L. The sample from a fraction presents a chromatogram with single peak 
(Figure 3.4). So it can be assumed that α-mangostin was isolated nearly pure using HPCCC 
according to HPLC peak area at this UV wavelength. 
3.7 Solvent System Selection and Partition Coefficient (KD) Measurement 
Table 3.7 Partition coefficient (KD) as the results of 2.3.2.1.  
No Solvent 
System 
(v/v) 
Concentration of 
α-mangostin in UP 
(Mean ± SD) 
Concentration of 
α-mangostin in LP 
(Mean ± SD) 
Partition 
Coefficient (KD) 
1 HEMWat 
(1:1:1:1) 
0.0494 ± 0.0002 0.0024 ± 0.0001 19.65 - 21.37 
2 HEMWat 
(5:5:10: 4) 
0.0328 ± 0.0004 0.0333 ± 0.0009 0.97 – 1.00 
3 HEMWat 
(8:8:10:6) 
0.0570 ± 0.0001 0.0174 ± 0.0003 3.23 – 3.32 
4 HEMWat 
(10:5:5:1) 
0.0186 ± 0.0003 0.0458 ± 0.0008 0.40 – 0.40 
 Note that HEMWat refers to the solvent system consisting of hexane-ethyl acetate-
methanol-water. Selection of the solvent system for the separation of compounds by 
HPCCC requires consideration of the partition coefficient (also called the distribution ratio) 
and the settling time of the phase system. It can be seen in the Table 3.7 that the hexane-
ethyl acetate-methanol-water (HEMWat) (5:5:10:4 v/v) provided a partition coefficient 
(KD) of 0.97 – 1.00. This meets the requirement of the suitable KD value which is 0.5 ≤ KD 
≤ 2.0 for separation using HPCCC. This phase system was selected as solvent system for 
isolation and purification of α-mangostin from the fruit rinds of Garcinia mangostana L. 
using HPCCC. If KD=1, the analyte will elute at the retention volume equal to the column 
capacity regardless of the retention volume of the stationary phase (Ito, 2005). Having 
KD=1 is a good point since the concentration of Component dissolved in UP is equal to the 
LP. The separation can also be conducted either in normal phase or reverse phase by simply 
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changing LP to stationary phase or mobile phase. In the present study, the separation was 
selected with reverse phase mode since this solvent system was prepared classically using a 
separating funnel it produced the LP volume almost 3 times more than the UP volume. So it 
was better to choose reverse phase mode to balance solvent usage where more mobile phase 
was needed than stationary phase.  
3.8 Settling Time Measurement 
Table 3.8 Settling time of HEMWat (5:5:10:4 v/v) solvent system (2.3.2.2) 
No Settling Time (sec) 
1 9.45 
2 8.37 
3 9.12 
Mean ± SD 8.98 ±0.55 
  
The table above shows the average of settling time of solvent system selected i.e. 
HEMWat (5:5:10:4 v/v) was 8.98 sec. To provided satisfactory retention of the stationary 
phase over 50% of the total column capacity in a proper range of flow rates, the time 
required for the two phases to form clear layers with a distinct interface is less than 20 sec 
(Ito, 2005), so the solvent system selected met the requirement. 
3.9 Study on Extraction Kinetics Using Rotary Wheel 
Table 3.9 Percentage of α-mangostin extracted from the fruit rind of Garcinia 
mangostana L. in HEMWat (5:5:10:4 v/v) 
No 
 Time UP 
(%) 
LP 
(%) 
UP+LP 
(%) 
1 30 min 2.77 2.79 2.82 
2 60 min 2.7 2.91 2.94 
3 90 min 2.79 2.91 2.96 
4 180 min 2.98 3.02 3.08 
5 360 min 2.94 3.17 3.05 
6 Overnight 2.93 2.93 3.10 
7 2 Days 3.22 3.09 3.22 
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Figure 3.5 below shows the extraction of approximately 0.025 g of rinds with 25 ml 
of either upper phase, lower phase or total phase that the α-mangostin extracted was 
approximately 2.8% of the rind in just 30 min after rotation on a rotary wheel. There was 
no significantly different percentage of α-mangostin extracted in UP, LP as well as UP+LP 
of the HEMWat (5:5:10:4 v/v) phase system. The percentage of α-mangostin then increased 
a little bit and reached at nearly 3% after 60 min rotation. This condition has remained 
relatively stable for 2 days rotation, with the variation observed being assumed to be simple 
experimental error. 
 
 Figure 3.5. Extraction kinetic of α-mangostin from the fruit rinds of Garcinia 
mangostana L. (Percent vs. Time) with either upper, lower or totals phase system 
(HEMWat 5:5:10:4 v/v) 
3.10 Sample Loading Study 
Sample loading study was conducted on an analytical scale Mini HPCCC 
instrument. This method was a modification of the method described by Jia et al (2011) for 
the isolation of major xanthones in Swertia mussotii using Centrifugal Partition 
Chromatodraphy. The solvent system was selected based on the solvent that is commonly 
used for the isolation and separation of natural materials by liquid flow processing, which is 
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generally composed of hexane or heptane /ethyl acetate/methanol/water and is called 
HEMWat. Applying the solvent system of hexane/ethyl acetate/methanol/water (5:5:10:4 
v/v) for isolation of α-mangostin from fruit rinds of Garcinia mangostana L. provided a 
suitable distribution ratio (KD=1) as mentioned above. The running conditions which 
several parameters can be seen on Table 3.10 as follows:  
Table 3.10 Optimised conditions of sample loading study 
No Parameters Optimised Conditions 
1 Instrument Mini HPCCC 
2 Column volume 17.4 mL 
3 Bore 0.8 mm 
4 Solvent system HEMWat (5:5:10:4 v/v)* 
5 Stationary phase Upper phase 
6 Mobile phase Lower phase 
7 Running mode Reverse phase 
8 Rotational speed  2100 rpm 
9 Flow rate 1 mL/min 
10 Temperature 25 ⁰C 
11 Run time per injection 25 min 
12 Number of injections Up to 10 x 
*H stands for hexane 
Samples injected were a variety of extract amounts from 4.6 mg to 91.2 mg and 
volumes from 0.86 mL to 1.8 mL. The experiments were done with single and multiple 
injections up to 10 times with 25 min interval time between injections without any 
replacement or topping up of the stationary phase. The interval time was considered based 
on the elution time of α- mangostin that generally eluted after 17 min to 23 min using the 
method conditions above. 
Table 3.11 below shows the results of sample loading study. Ethanol extract that 
was injected on Mini HPCCC up to 22.8 mg, showed a good separation and provided high 
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purities and yields with high recoveries. The purity reached at least 98% and yield over 97 
% with recovery not less than 99% in average. The resolutions were also good for most 
injections from 4.6 mg – 22.8 mg crude extract. It can be seen on fractograms (an elution 
chromatogram recontructed from the off-line analysis data) at Figure 3.6 to Figure 3.10. 
below, the peaks of α- mangostin were separated well in most injections; however the 
resolution decreased a little with the increasing number of injections, as well as 
concentration of sample injected. This phenomenon probably occurs because more 
viscous/concentrated samples injected into the solvent system will create a resistance/shock 
of the solvent system that will cause a loss of stationary phase and dilation of the peak 
(Berthod, 2009). The multiple injections with a long running time affected the loss of 
stationary phase on Mini HPCCC. On the fractograms can be seen clearly that the distance 
between α- mangostin peaks and other components were getting closer and closer with the 
increasing number of injections of 9.1 mg sample injected in 10 injections (Figure 3.7). 
This also happened with sample injected up to 22.8 mg with 5 injections (Figure 3.8. to 
Figure 3.11). However, all of them still had good resolutions with a value above 1.5. 
Sample injected with concentration 45 mg - 47 mg as shown on Figure.3.11 and 
Figure 3.12 provided acceptable resolution; however the purities and yields decreased and 
the recoveries were low. When the amount of injection was increased two times (91.2 mg); 
the peaks of α-mangostin and all other compounds lost resolution and became overlapping 
(Figure 3.13). It also affected the purity, yield, as well as recovery which was significantly 
down. For this reason the concentration of 22.8 mg ethanol extract (SM-22 on Figure 3.11) 
was selected as a sample injected for further study on development of an efficient method 
for productions of purified α- mangostin using liquid flow processing. 
The percentage of stationary phase left was calculated and presented as initial % SF 
as %SF before injection and final %SF as %SF after the last injection. The %SF can be seen 
on each fractogram on Figure 3.6 – Figure 3.22 below. 
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Table 3.11 Sample loading study on Mini HPCCC (17.4 mL coil; 0.8 mm bore) 
Running 
Code 
Sample 
amount per 
injection 
(mg) 
Number 
of 
Injections  
Resolution* 
(Mean ± 
SD) 
Total            
α-Mangostin 
Isolated (mg) 
Throughput 
Sample 
Process (g/h) 
Throughput 
α-Mangostin 
Isolated (g/h) 
Purity 
(Mean ± SD)  
(%) 
Yield 
(Mean ± SD) 
 (%) 
Recovery  
(%) 
SM-20 4.6 5 2.04 ± 0.29 6.6 0.01 0.003 99.59 ± 0.28 99.42 ± 0.53 99% 
SM-16 9.1 10 1.98 ± 0.24 36.8 0.02 0.01 97.81 ± 0.57 97.17 ± 2.30 98.75 
SM-17 13.7 5 2.24 ± 0.26 22.4 0.03 0.01 98.74 ± 0.88 98.54 ± 0.43 97.05 
SM-18A 18.2 5 1.83 ± 0.39 29.5 0.04 0.01 98.50 ± 0.99 97.44 ± 1.27 99% 
SM-19 22.8 5 1.82 ± 0.18 30,6 0.06 0.02 98.82 ± 0.18 93.68 ± 1.67 99% 
SM-22 45.6 1 1.33 12.7 0.11 0.03 96.87 98.98 60.2 
SM-23 47.8 1 1.44 14.2 0.11 0.03 97.85 95.61 57.5 
SM-21 91.2 1 0.67 21.7 0.22 0.05 94.69 92.38 67.1 
*Resolution of α-mangostin from the component 3 
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Figure 3.6 Fractogram of SM-20; Mini-17.4 mL; HEMWat (5:5:10:4 v/v); RP; 2100 rpm; 25⁰C; 1 mL/min; 5 consecutive 
injections of the same amount of 4.6  mg ethanol extract in 0.86 mL without any charge of the SP with initial to final %SF=69% 
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Figure 3.7 Fractogram of SM-16; Mini-17.4 mL; HEMWat (5:5:10:4 v/v); RP; 2100 rpm; 25⁰C; 1 mL/min; 10 consecutive 
injections of the same amount of 9.1 mg ethanol extract in 0.86 mL without any charge of the SP with initial %SF=69%  and final 
%SF=68% 
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Figure 3.8 Fractogram of SM-17; Mini-17.4 mL; HEMWat (5:5:10:4 v/v); RP; 2100 rpm; 25⁰C; 1 mL/min; 5 consecutive 
injections of the same amount of 13.7  mg ethanol extract in 0.86 mL without any charge of the SP with initial %SF 69% and final 
%SF 62% 
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Figure 3.9 Fractogram of SM-18A; Mini-17.4 mL; HEMWat (5:5:10:4 v/v); RP; 2100 rpm; 25⁰C; 1 mL/min; 5 consecutive 
injections of the same amount of 18.2 mg ethanol extract in 0.86 mL without any charge of the SP with initial %SF=69% and final 
%SF=61%   
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Figure 3.10 Fractogram of SM-19; Mini-17.4 mL; HEMWat (5:5:10:4 v/v); RP; 2100 rpm; 25⁰C; 1 mL/min; 5 consecutive 
injections of the same amount of 22.8 mg ethanol extract in 0.86 mL without any charge of the SP with initial %SF=69% and final 
%SF=61% 
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Figure 3.11 Fractogram of SM-22; Mini-17.4 mL; HEMWat (5:5:10:4 v/v); RP; 2100 rpm; 25 ⁰C; 1 mL/min; single 
injection of 45.6 mg ethanol extract in 0.86 mL LP with initial %SF=72% and final %SF=56% 
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Figure 3.12 SM-23; Mini-17.4 mL; HEMWat (5:5:10:4 v/v); RP; 2100 rpm; 25 ⁰C; 1 mL/min; single injection of 47.8 mg 
ethanol extract in 1.8 mL LP with initial %SF=72% and final %SF=52% 
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Figure 3.13 Fractogram of SM-21 Mini-17.4 mL; HEMWat (5:5:10:4 v/v); RP; 2100 rpm; 25 ⁰C; 1 mL/min; single injection 
of 91.2 mg ethanol extract in 0.86 mL LP with initial %SF=72% and final %SF=40%  
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3.11 Efficient Method for Production of α-Mangostin  
An efficient method for production of  purified α-mangostin using liquid flow 
processing was developed based on the results from the sample loading study on an 
analytical scale Mini HPCCC instrument that was mentioned above. Using the optimum 
concentration of 22.8 mg crude extract on Mini; the sample was then scaled up 8 times on 
semi preparative Spectrum HPCCC instrument and 50 times on preparative Midi HPCCC 
Instrument for developing an efficient HPCCC method. The running conditions for those 
instruments are described on table 3.12 below: 
Table 3.12 Optimised conditions for development of an efficient method for 
production of α-mangostin using HPCCC 
No Parameters Mini  
HPCCC 
Spectrum 
HPCCC 
Midi  
HPCCC 
1 Coil volume (mL) 17.4 143.5 912.5 
2 Solvent system HEMWat 
(5:5:10:4) 
HEMWat 
(5:5:10:4) 
HEMWat 
(5:5:10:4) 
3 Flow rate (mL/min) 1  8 50 
4 Running Mode Reverse phase Reverse phase Reverse phase 
5 Temperature (⁰C) 25 25 25 
6 Rotational speed (rpm) 2100 1600 1400 
7 Elution time /injection 
(min) 
25 25 25 
8 Number of injections 5 2-10 5-7 
9 Extract amount per 
injection (mg) 
22.8 358.7 1281.1 
10 Sample volume per 
injection (mL) 
0.86 7 50 
11 Throughput α-
mangostin Isolated  
(g/h) 
0.02 0.05 0.88 
 
The method used only one step with multiple injections using the conditions as 
described above. This multiple injections without the replacement or topping up of the 
stationary phase that occurs in existing method, could save the use of solvents in particular 
the volume of stationary phase. It might be simply calculated using the following equation: 
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( )1−= NVV CX  
Where VX is volume of stationary phase saved; VC is volume of column; N is 
number of injections.  
In addition, multiple injections also saved the wasted time of pre and post CCC 
running for each injection i.e. filling the column, equilibration process and emptying the 
column. A similar equation is suitable to calculate the time saved as follows, 
( )1−= Ntt EX     
Where tX is time saved for column equilibration/emptying; tE is time of column 
equilibration/emptying process; N is number of injections. 
Using maximum concentration of sample injected for each instrument, this 
developed method not only reduced solvent and time consumption of the production 
process, reducing the cost of production, but also provided a high throughput with high 
purity and yield of α-mangostin as well as high recovery. The multiple injections method 
for producing the α-mangostin is efficient with the optimised conditions as shown on Table 
3.12. 
As in the previous running on Mini, scaling up 8 times on Spectrum and 50 times on 
Midi resulted in a similar elution time of α-mangostin at approximately 17 to 23 min. The 
scaling up factor is a simply obtained by dividing the bigger column volume with the 
smaller one. So the scale up factor is the result of the division between the column volume 
on Midi or Spectrum with the Mini column. This factor was then used for calculating the 
amount and the volume of the injection as well as the flow rate. Modification with 
increasing the concentration or the volume of the sample injected might be possible to 
obtaining a higher throughput in production process. However, the flow rate should be 
considered and might be reduced during injection time of a large volume or concentrated 
sample to avoid losing of stationary phase from the coil, as this leads to loss of resolution. 
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Table 3.13 Development of an efficient method for production of α-mangostin using liquid flow processing 
Running 
Code 
Extract 
amount 
per 
injection 
(mg) 
Instrument Coil 
volume 
(mL) 
Number of 
Injections 
Resolution* 
Mean±SD 
Total              
α-mangostin 
Isolated (mg) 
Throughput 
Sample 
Process 
 (g/h) 
Throughput 
α-mangostin 
Isolated  
(g/h) 
Purity 
Mean±SD  
(%) 
Yield 
Mean±SD  
(%) 
Recovery  
(%) 
SM-19 22.8 Mini 17.4 5 1.82±0.18 30.6 0.06 0.02 98.82±0.18 93.68±1.67 > 99 
SM-27A 22.0 Mini 17.4 5 1.66±0.20 31.3 0.05 0.02 98.09±0.61 97.86±2.78 > 99 
SM-28 21.9 Mini 17.4 5 1.59±0.15 38.0 0.05 0.02 98.13±1.11 94.68±3.62 98.6 
SM-29 178.3 Spectrum 143.5 5 2.34±0.10 164.1 0.43 0.08 99.19±0.34 95.43±2.97 91.1 
SM-30 178.3 Spectrum 143.5 10 2.06±0.30 343.5 0.43 0.08 99.24±0.26 96.35±1.56 > 99 
SM-33 358.7 Spectrum 143.5 2 2.24±0.11 43.4 0.86 0.05 99.34±0.43 99.61±0.55 > 99 
SM-26 1281.1 Midi 912.5 5 1.73±0.09 1673.4 3.07 0.80 98.32±0.36 95.56±4.56 98.3 
SM-28A 1273.8 Midi 912.5 7 1.63±0.18 2552.8 3.06 0.88 98.24±0.82 94.42±4.64 > 99 
SM-34 708.6 Spectrum 143.5 3 1.26±0.06 195.1 1.7 0.16 96.38±1.48 94.97±2.14 43.6 
SM-37 496.0 Spectrum 143.5 5 1.46±0.21 424.3 1.20 0.20 98.11±1.71 93.81±3.37 81.2 
*Resolution of α-mangostin from component 3 
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The fractograms at Figure 3.14 to Figure 3.20 described the CCC running during 
development of an efficient method for production of α-mangostin using CCC.  The 
fractograms shows  that α-mangostin was well separated using any scale of CCC apparatus 
from analytical to preparative. This can be determined from the values of resolution which 
are displayed on Table 3.13. All resolutions were acceptable, with value at least 1.59. 
Having a good resolution allowed increasing either the concentration or the volume of 
sample injected which means increasing the throughput of sample processing and 
production of the α-mangostin as well.  
Figure 3.16 to Figure 3.18 shows that the peaks of α-mangostin looked different 
with the α-mangostin peaks obtained from samples stored in methanol. Usually α-
mangostin peak has the highest peak in the fractogram  as shown on Figure 3.3. However  
in  Figs 3.16-3.18, the mangostin peak  was smaller than target no 2 especially for the run 
SM-33 (figure 3.18) where the sample was the most unfresh one, having been stored for 
more than a week in LP. These mean that the ethanol extract of mangosteen was more 
unstable in LP than in methanol.  
Table 3.13 also presents the purities of α-mangostin produced in one step using any 
scale of CCC machine. In general, the Spectrum HPCCC produced the highest purity of α-
mangostin at >99% compared to those on Mini and Midi, which produced a bit lower 
roughly 98%. Although the separation was conducted with  10 injections on SM-30, the 
resolution was still very good. It can be seen on Figure 3.17. The α-mangostin was well 
separated from the other compounds with resolution value of 2.06 ± 0.30; and obtained 
very high purity at 99.24 ± 0.26 % with 96.35 ± 1.56% yield and nearly 100% recovery. 
This pure α-mangostin had purity  acceptable for use as a reference standard for quality 
control of mangosteen based products and also for marker quantitative analysis and 
standardization of the raw materials and preparations from mangosteen plant (Pothitirat and 
Gritsanapan, 2009). This is very important since mangosteen is one of the medicinal plants 
where components often depend on the place where it grew.  
Based on the results of Spectrum HPCCC on SM-30, the concentration of sample 
injected was increased 2 times to 358.7 mg (SM-33). Two injections with this twice higher 
concentration obtained an equal percentage of purity at 99.34 ± 0.43 % with a higher yield 
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at 99.34 ± 0.43%. So, the sample injected was then increased again with a larger amount of 
496 mg extract in 7 mL with 5 injections (SM-37) and 708.6 mg extract in 10 mL with 3 
injections (SM-34). The experiments resulted α-mangostin isolated with the purity 98.11% 
and 96.38%  by HPLC peak area and the yield 93.81% and 94.97% respectively. However 
the recovery decreased to 81.2% on SM-37 and 48.6% on SM-34. It can be concluded that 
the production of α-mangostin in preparative scale using Spectrum HPCCC with all 
conditions as mentioned above was optimum and  α-mangostin was obtained with high 
purity, yield and recovery when  injecting a sample with the concentration approximately 
450 mg / 7 mL (65 mg/mL) aqueous ethanol extract of the fruit rind of Garcinia 
mangostana L in LP with maximum volume of 10 mL. α-Mangostin with the purity at 
minimum 98% is acceptable to be used as a reference standard for quality control of 
mangosteen based products. This method was also efficient because up to 5 injections were 
possible without replacement or topping up the stationary phase, the separation was kept in 
stable with acceptable resolution value at 1.46±0.21. 
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Figure 3.14 Fractogram of SM-27A; Mini-17.4 mL; HEMWat (5:5:10:4 v/v); RP; 2100 rpm; 25⁰C; 1 mL/min; 5 consecutive 
injections of the same amount of 22.0 mg ethanol extract in 0.86 mL without any charge of the SP with initial %SF=66% and final 
%SF=60% 
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Figure 3.15 Fractogram of SM-28; Mini-17.4 mL; HEMWat (5:5:10:4 v/v); RP; 2100rpm; 25⁰C; 1 mL/min; 5 consecutive 
injections of the same amount of 21.9 mg ethanol extract in 0.86 mL LP without any charge of the SP with initial %SF=69% and 
final %SF=61% 
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Figure 3.16 Fractogram of SM-29; Spectrum-143.5 mL; HEMWat (5:5:10:4 v/v); RP-1600 rpm; 25⁰C; 8 mL/min; 5 
consecutive injections of the same amount of 178.3 mg ethanol extract in 7 mL LP without any charge of the SP with initial 
%SF=93% and final %SF=79% 
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Figure 3.17 Fractogram of SM-30; Spectrum-143.5 mL; HEMWat (5:5:10:4 v/v); RP-1600 rpm; 25oC; 8 mL/min; 10 
consecutive injections of the same amount of 178.3 mg ethanol extract in 7 mL LP without any charge of the SP with initial 
%SF=77% and final %SF=63% 
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Figure 3.18 Fractogram of SM-33; Spectrum-143.5 mL; HEMWat (5:5:10:4 v/v); RP; 1600 rpm; 25⁰C; 8 mL/min; 2 
consecutive injections of the same amount of 358.7 mg ethanol extract  in 7 mL LP without any charge of the SP with initial 
%SF=81% and final %SF=68% 
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Figure 3.19 Fractogram of SM-26; Midi-912.5 mL; HEMWat (5:5:10:4 v/v); RP; 1400 rpm; 25oC; 50 mL/min; 5 
consecutive injections of the same amount of 1281.1 mg ethanol extract in 50 mL LP without any charge of the SP with initial 
%SF=85% and final %SF=57% 
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Figure 3.20 Fractogram of SM-28A; Midi-912.5 mL; HEMWat (5:5:10:4 v/v); RP; 1400 rpm; 25oC; 50 mL/min; 7 
consecutive injections of the same amount of 1273.8 mg ethanol extract in 50 mL LP without any charge of the SP with initial 
%SF=82% and final %SF=58% 
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Figure 3.21 Fractogram of SM-34; Mini-143.5 mL; HEMWat (5:5:10:4); RP; 1600 rpm; 25oC-8mL/min; 3 consecutive 
injections of the same amount of 708.6 mg ethanol extract in 10mL LP without any charge of the SP with initial %SF=76% and final 
%SF=38% 
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Figure 3.22 Fractogram of SM-37; Mini-143.5 mL; HEMWat (5:5:10:4); RP; 1600 rpm; 25oC-8mL/min; 5 consecutive 
injections of the same amount 496 mg ethanol extract in 7mL LP without any charge of the SP with initial %SF=90% and final 
%SF=61% 
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Identification and characterisation of isolated α-mangostin by NMR was provided 
and interpreted by Kingston University, London. The identified sample was from SM 23 
which was run with a single injection on Mini. It was a combined pure fractions (F20 and 
F21) which had a single peak on analytical HPLC. (Figure 3.23 and 3. 24) 13C-NMR and 1 
H-NMR on fractions 20-21 which ran similarly to  an α-mangostin commercial reference 
standard, indicated α-mangostin. There was a ketone region at the spectral line of 183.1690 
ppm, the six spectral lines in the 15 – 30 ppm. range suggesting –CH2 or –CH3 carbons. 
The spectral line at 61.9 ppm indicated the presence of a –CH2 or –CH3 attached to an 
oxygen while spectral lines in the 90 – 155 ppm range indicated the presence of alkenes, 
benzenes or other hetero aromatics. The spectral lines that show up in the 160 – 170 ppm 
range indicated the presence of an anhydride of some description or a carbon directly 
bonded to oxygen. This spectrum also showed a 24 carbon structure, which fits with α-
mangostin. 
The spectral lines in the 1.6 – 1.8 ranges from proton spectrum suggested the 
presence –CH3 protons. The three spectral lines in the 3.0 – 4.2 ppm range suggested the 
presence of carbons bonded to nitrogen, oxygen or a halogen; although, in this situation, it 
was likely to represent a carbon bonded to oxygen. The large multiplet at 5.2 ppm could 
represent a –CH-O or –CH-Halogen pairing, however it could also represent a non-
conjugated alkene. The spectral lines between 6 – 8 ppm suggested protons in the aromatic 
region while the spectral line at 13.5 ppm suggested the presence of aldehydes.  
Looking at the COSY spectrum and HSQC spectrum for EKSM23F2021 and 
compared to the standard, it was finally concluded that the sample had chemically structure 
of α-mangostin as follows: 
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Figure 3.23 Chemical structure of EKSM23F2021 on NMR  
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Figure 1 COSY spectrum of a-mangostin standard in chloroform 
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Figure 3.25 HSQC spectrum of a-mangostin standard in chloroform 
 
89 
 
 
 
Figure 3.26 Carbon spectrum of EKSM23F2021
 
which had a single peak on HPLC was identified as α-mangostin on NMR 
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Figure 3.27 Proton spectrum of EKSM23F2021 which had a single peak on HPLC was identified as α-mangostin on NMR 
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Figure 3.28 COSY spectrum of EKSM23F2021 
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Figure 3.29 HSQC spectrum of EKSM23F2021 
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Chapter 4 SUMMARY AND CONCLUSIONS 
4.1 SUMMARY 
Table 4.1.1  Optimum Conditions for Analysis of α-mangostin on HPLC 
No HPLC Parameters Optimum Conditions of HPLC 
1 Column Agilent Zorbax Bonus RP C18 with dimension (3.5um; 4.6x150mm) 
2 Temperature 40 ⁰C 
3 Flow rate 0.5 mL/min 
4 Mobile phase Methanol with 0.05% TFA (C) Water with 0.05% TFA (D) 
5 Elution program 
Gradient system: 
0-3 min: 95-100% C; 
3-8 min: 100% C; 
6 Run time 12 min 
7 
Delay time 
between injection 2 min 
8 Collecting data 12 min 
9 Wave length detection PDA Max Plot 210 nm to 400 nm 
10 Low limit of detection (LLOD) 0.000008 µg/µL (8 ppm) 
11 
Retention time of 
α-mangostin 
(min) 
6.00 - 6.50 
 
Table 4.1.2 Optimum conditions of sample loading study 
No Parameters Optimum Conditions 
1 Instrument Analytical Mini HPCCC 
2 Column volume 17.4 mL 
3 Bore 0.8 mm 
4 Solvent system HEMWat (5:5:10:4 v/v)* 
5 Stationary phase Upper phase 
6 Mobile phase Lower phase 
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7 Elution mode Reverse phase 
8 Rotational speed 2100 rpm 
9 Flow rate 1 mL/min 
10 Temperature 25 ⁰C 
11 Run time per injection 25 min 
12 Optimum amount of 
sample injected (mg) 22.8 
13 Volume of sample (mL) 0.86 
14 Number of injections Up to 10 times 
*H stands for hexane 
Table 4.1.3 Optimum Conditions for Production of α-mangostin using HPCCC 
No Parameters Spectrum HPCCC Midi HPCCC 
1 Coil volume (mL) 143.5 912.5 
2 Solvent system HEMWat (5:5:10:4) HEMWat (5:5:10:4) 
3 Flow rate (mL/min) 8 50 
4 Running Mode Reverse phase Reverse phase 
5 Temperature (⁰C) 25 25 
6 
 
Rotational speed 
(rpm) 1600 1400 
7 
Elution time 
/injection (min) 25 25 
8 Number of injections 2-10 5-7 
9 Extract amount per injection (mg) 358.7 1281.1 
10 Sample volume per injection (mL) 7 50 
11 
Throughput α-
mangostin Isolated 
(g/h) 
0.05 0.88 
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4.2 CONCLUSIONS 
It can be concluded that an efficient method for production of α-mangostin using 
liquid flow processing on HPCCC with multiple injections using optimum condition as 
mentioned above was as follows:  
1. Multiple injections without replacement or topping up the stationary phase. This could 
save solvent use especially on stationary phase equal to the volume of stationary phase 
used for the dynamic equilibration multiplied by the following injections number. This 
means a lower cost of production. 
2. Reduce time consuming compared to single injection as existing method since any 
number of injections only needs once column equilibration and once column 
empty/washing. So, it should be faster to isolate the same amount of α-mangostin with 
the developed method. 
3. In this research, the most efficient method for production of α-mangostin using liquid 
flow processing was on semipreparative HPCCC with the optimum concentration of 
sample injected approximately 65 mg/mL with maximum volume of 10 mL per 
injection. 
The prediction of solvent system and time consumed on various HPCCC 
instruments can be seen on the Table 4.1.4 and Table 4.1.5 below: 
Table 4.1.4 Prediction of solvent system consumed on various HPCCC instruments 
No Parameters 10 continous injections 
Mini Spectrum Midi 
1 Coil volume (mL) 20 22 and 132 1000 
2 Stationary Phase saving for 
column equilibration (mL) 
9x20=180 9x154=1,386 9x1000=9,000 
3  Mobile Phase saving for 
column equilibration (mL) 
9x20=180 9x100=900 9x700=6,300 
 Total solvent saving (mL) 360 2,286 15,300 
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Table 4.1.5 Prediction of time consumed on various HPCCC instruments  
No Parameters 10 continous injections 
Mini Spectrum Midi 
1 Time saving for column 
equilibration (min) 
9x15=135 9x15= 135 9x15=135 
2 Time saving for column 
empty (min) 
9x10=90 9x30=270 9x30=270 
3 Time saving for column 
washing (min) 
9x5=45 9x10=90 9x10=90 
4 Total time saving (hours) 4.5 8.25 8.25 
 
4.3  FUTURE WORK 
 The future work that can be recommended regarding this project includes:   
1. Scale up for production of α-mangostin on preparative and industrial scale, based on the 
optimum concentration of injected sample on Spectrum HPCCC.  
2. Separation and isolation of component 4, which had the same UV spectrum but 
different retention time to α-mangostin. The isolated compound can then be assayed for 
the bioactivities as for α-mangostin because having the same UV active component may 
have similar bioactivities.  It might be an isomer of mangostin. 
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